

Customer No. 000959

Case Docket No. GIN-005

THE ASSISTANT COMMISSIONER FOR PATENTS  
Box Patent Application  
Washington, D.C. 20231

"Express Mail" Mailing Label Number EM284252488US

Date of Deposit February 20, 1998

I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Signature

Ilidio P. Cardoso

Please Print Name of Person Signing

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Carl H. June, et al.

For: METHODS FOR MODULATING EXPRESSION OF AN HIV-1 FUSION COFACTOR

Enclosed are:

- ☐ This is a request for filing a ☐ continuation ☐ divisional application under 37 CFR 1.53(b), of pending prior application serial no. \_\_\_\_\_ filed on \_\_\_\_\_ entitled \_\_\_\_\_.
- ☒ 44 pages of specification (including 4 pages of sequence listing), 5 pages of claims, 1 pages of abstract.
- ☒ 9 sheets of drawings.
- ☒ An unexecuted Declaration, Petition and Power of Attorney.
- ☐ An assignment of the invention to \_\_\_\_\_, A recordation form cover sheet (Form PTO 1595) is also enclosed.
- ☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 37 C.F.R. 1.27.
- ☒ Other Transmittal Letter for Diskette of Sequence Listing and Diskette of Sequence Listing

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE	//////////	
TOTAL CLAIMS	54 - 20	= 34
INDEP. CLAIMS	5 - 3	= 2
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		

\* If the difference in Col. 2 is less than zero,  
enter "0" in Col. 2.

SMALL ENTITY	
RATE	FEE
//////////	\$
x 11=	\$
x 41	\$
+135	\$
TOTAL	0

OTHER THAN SMALL ENTITY	
RATE	FEE
//////////	\$ 790
x 22=	\$ 748
x 82	\$ 164
+270	\$
TOTAL	\$1702.00

- ☐ Please charge my Deposit Account No. 12-0080 in the amount of \$ .  
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-0080.  
A duplicate copy of this sheet is enclosed.

1-574 U.S. PTO  
02/20/98

09027205.022090

- ☐ Any additional filing fees required under 37 C.F.R. 1.16.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 12-0080.  
A duplicate copy of this sheet is enclosed.
- ☐ Any patent application processing fees under 37 C.F.R. 1.17.
- ☐ The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).
- ☐ Any filing fees under 37 C.F.R. 1.16 for presentation of extra claims.
- ☐ A check in the amount of \$\_\_\_\_\_ to cover the recording of assignment documents is also enclosed.
- ☒ Address all future communications (May only be completed by applicant, or attorney or agent of record) to Amy E. Mandragouras at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP  
28 State Street  
Boston, Massachusetts 02109

Date: February 20, 1998

LAHIVE & COCKFIELD, LLP  
Attorneys at Law

By Jane E. Remillard  
Jane E. Remillard, Reg. No. 38,872  
for Amy E. Mandragouras,  
Reg. No. 36,207  
28 State Street  
Boston, MA 02109  
(617) 227-7400  
Telecopier (617) 742-4214

## METHODS FOR MODULATING EXPRESSION OF AN HIV-1 FUSION COFACTOR

### Related Applications

- 5        This application claims priority to U.S. provisional Application No. 60/037,422, filed on February 21, 1997, the contents of which are incorporated herein by reference.

### Background of the Invention

- A variety of immune factors influences the susceptibility of CD4 T cells to HIV-1 infection, including soluble factors and the state of T cell differentiation. Evidence for the importance of these host factors includes the observation that lymphocytes from different donors are not equally infectable with HIV-1, raising the possibility that resistance of lymphocytes to HIV infection in vitro might be associated with different rates of disease progression (Spira, A. I. and D. D. Ho. 1995. *J. Virol.* 69:422; and Wainberg, M. A., N. Blain, and L. Fitz-Gibbon. 1987. *Clin. Exp. Immunol.* 70:136). Host factors that are recognized to affect the susceptibility of CD4 cells to HIV infection include factors intrinsic to the CD4 cell and indirect factors. Among the direct factors of recognized importance are CD4 and fusion coreceptor(s) expression. The density of CD4 receptors expressed on the cell surface influences the efficiency of HIV-1 infection (Kabat, D., 1994. *J. Virol.* 68:2570; and Brand, D., 1995. *J. Virol.* 69:166). Recently chemokine receptors have been identified as a critical determinant of susceptibility to infection with HIV-1. Macrophage-tropic strains of HIV-1 utilize CCR5 as a fusion cofactor (Alkhatib, G., 1996, *Science* 272:1955; Doranz, B. J., 1996 *Cell* 85:1149; Choe, H., 1996. *Cell* 85:1135; Dragic, T., 1996. *Nature* 381; Deng, H., 1996. *Nature* 381:661) while T cell tropic strains of HIV-1 employ CXCR4/fusin as a coreceptor (Feng, Y., 1996. *Science* 272:872). The importance of these coreceptors is illustrated by the recent observation that some multiply exposed individuals who remain uninfected with HIV-1 have mutations in CCR5 (Liu, R., 1996. *Cell* 86:367; Dean, M., 1996. *Science* 273:1856).
- Indirect factors may also be important in determining the resistance of CD4 cells to HIV-1 infection. Most of the described effects have depended on CD8 cells. Levy and coworkers first reported that CD8 T cells from HIV-infected individuals were capable of suppressing endogenous viral replication at a transcriptional level in CD4 T cells from HIV-infected individuals (Walker, C. 1986. *Science* 234:1563). Suppression was mediated by a non-cytolytic, MHC-nonrestricted mechanism (Mackewicz, C. E., 1995. *Proc. Natl. Acad. Sci U.S.A.* 92:2308). The C-C chemokines RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$  have been shown to inhibit infection of M-tropic isolates, but not T cell tropic strains of HIV-1 (Cocchi, F., 1995. *Science* 270:1811). The potential importance of

09027205-022008

these findings were underscored by a report from Paxton and coworkers indicating that CD4 cells from people who were repeatedly exposed to HIV but remain uninfected, were resistant to infection with HIV (Paxton, W. A., 1996. *Nat. Med.* 2:412). They found that these resistant individuals secreted higher levels of C-C chemokines in vitro. Multiple distinct HIV-1 suppressive activities appear to be secreted or shed by CD8 cells (Barker, T. D., 1996. *J. Immunol.* 156:4476). IL-2 and IL-16 have also been proposed to inhibit HIV replication via CD8 cell mediated mechanisms (Kinter, A. L., 1995. *Proc. Natl. Acad. Sci. U.S.A.* 92:10985; Baier, M., A. 1995. *Nature* 378:563). IL-10 and TGF- $\beta$  have also been shown to have inhibitory effects on HIV-1 replication (Fauci, A. S. 1996. *Nature* 384:529).

Recent studies have shown that while specificity of T cell activation is dictated by antigen receptor signals, effective activation requires at least one costimulatory signal. CD28 is the dominant costimulatory signal, and interaction of CD28 with its counter receptors CD80 or CD86 is required for the induction of many cellular immune responses (June, C. H., 1994. *Immunol. Today* 15:321). We recently reported that CD28 stimulation could mediate an antiviral effect (Levine, B. L., 1996. *Science* 272:1939). The effect was potent as CD4 cells from HIV-infected donors could be routinely propagated in culture without virus replication in the absence of antiretroviral drugs. The CD28-mediated effect was distinguished from previous reports in that the inhibition acted early in the viral life cycle and appeared to be independent of CD8 T cells.

### **Summary of the Invention**

This invention pertains to methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28 or CTLA-4. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.

The methods of the invention can be used to modulate HIV-1 fusion cofactor expression *in vivo* or *ex vivo* by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated *in vivo* by administration of an agent, e.g., an anti-CD28 or an anti-CTLA-4 antibody, which stimulates or allows stimulation of a CD28-associated signal in a T cell of a subject. Alternatively, T cells can be obtained from a subject and contacted with an agent which stimulates (or allows stimulation of, e.g., a

soluble CTLA4 antibody or fragment thereof, e.g., Fab fragment) a CD28-associated signal in the T cell to thereby inhibit or downregulate expression of an HIV-1 fusion cofactor *ex vivo*. Such methods are useful for the treatment of an individual having an HIV-1 infection, e.g., a chronic HIV-1 infection. In preferred embodiments, the agent is co-administered with another treatment, e.g., an influenza vaccine. The agent is administered in an amount effective to downregulate the HIV-1 fusion cofactor. In other preferred embodiments, the level of HIV-1 fusion cofactor expression is determined using, for example, Northern blot analysis, *in situ* hybridization, or cell staining. In yet further preferred embodiments, the level of viral load or viral burden in an HIV infected subject is determined following administration of an agent which stimulates or allows stimulation of a CD28-associated signal in the T cell.

The invention also pertains to compositions comprising an effective amount of an agent that downregulates an HIV-1 fusion cofactor, e.g., CCR5, expression by stimulating one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule (e.g., an anti-CD28 antibody, a B7-1 or a B7-2 ligand). Another embodiment of the invention pertains to compositions comprising an effective amount of an agent which allows stimulation of a CD28-associated signal in the T cell by, for example, blocking the interaction of B7 molecules with CTLA4 (e.g., CTLA4 antibodies or fragments thereof), thereby allowing B7 molecules to interact and stimulate a CD28-associated signal in the T cell. Such agents can be coupled to a solid phase surface (e.g., a biodegradable bead) which may additionally include an agent that provides a primary activation signal to the T cell (e.g., an anti-CD3 antibody) coupled to the same or different solid phase surface. Furthermore, the invention provides kits comprising the compositions, including instructions for use.

Another aspect of the invention pertains to screening assays for identifying inhibitors or activators of expression of an HIV-1 fusion cofactor, such as CCR5, in a cell following stimulation or inhibition of one or more intracellular signals which result from ligation of a surface receptor on the cell which binds a costimulatory molecule, such as CD28. In one embodiment, a T cell which expresses a cell surface receptor (e.g., CD28 or CTLA-4) which binds a costimulatory molecule is utilized. To identify an inhibitor of expression of an HIV-1 fusion cofactor, such as CCR5, an intracellular signal transduction pathway associated with the receptor in the T cell (e.g., CD28) is stimulated in the presence of an agent to be tested and an inhibitor is identified based upon its ability to inhibit or downregulate expression of the HIV-1 fusion cofactor in the T cell.

### **Brief Description of the Drawings**

Figure 1 is a graph depicting the presence of p24<sub>Gag</sub> antigen by ELISA in CD4 cells stimulated with  $\alpha$ CD3/ $\alpha$ CD28 (open symbols) or PHA/IL-2 (filled symbols) infected with  $1 \times 10^4$  TCID<sub>50</sub> (median tissue culture infectious dose) of HIV<sub>US1</sub> (squares) or with  $1 \times 10^4$  MAGI (18) infectious doses of HIV<sub>NL4-3</sub> (circles).

Figure 2 depicts HIV-1 *gag* DNA sequences present in crude cell lysates quantitated using a PCR-based assay. Purified CD4<sup>+</sup> cells were stimulated with either PHA and IL-2 (lanes 1-4), or with beads coated with equal quantities of  $\alpha$ CD3/ $\alpha$ CD28 (lanes 5-8),  $\alpha$ CD3/ $\alpha$ MHC class I (lanes 9-12),  $\alpha$ CD3/ $\alpha$ CD2 (lanes 13-16),  $\alpha$ CD3/ $\alpha$ CD4 (lanes 17-20),  $\alpha$ CD3/ $\alpha$ CD5 (lanes 21-24) and  $\alpha$ CD3/ $\alpha$ CD7 (lanes 25-28). Three days post-stimulation,  $5 \times 10^6$  CD4<sup>+</sup> cells stimulated by each method were infected with  $10^4$  TCID<sub>50</sub> (median tissue culture infectious dose) of HIV<sub>Ba-L</sub>.  $1 \times 10^6$  cells were harvested immediately after virus addition (hour 0), post-virus washout (hour 2), and at designated time points thereafter.

Figure 3 depicts HIV-1 *gag* DNA sequences present in crude cell lysates quantitated using a PCR-based assay. Purified CD4<sup>+</sup> cells were stimulated with PHA/IL-2 (left panels) or  $\alpha$ CD3/ $\alpha$ CD28 (right panels) and infected with  $1 \times 10^4$  TCID<sub>50</sub> of the M-tropic isolates HIV<sub>US1</sub> and HIV<sub>Ba-L</sub> or  $1 \times 10^4$  MAGI infectious doses of the TCL-tropic isolate HIV<sub>NL4-3</sub>. Cells were harvested immediately after infection (lanes marked 0), as well as 2, 6, 12, 24, and 72 hours after infection and HIV DNA detected.

Figure 4 is a depiction of an analysis illustrating that the expression of chemokine receptor transcripts is differentially regulated in CD3/CD28-stimulated CD4<sup>+</sup> cells. RNA was isolated from unstimulated CD4<sup>+</sup> cells (lane 1) or from CD4 cells stimulated with PHA/IL-2 (lanes 2 and 3) or  $\alpha$ CD3/ $\alpha$ CD28 (lanes 4 and 5) at the indicated times post-stimulation using RNAsat (Teltest). 20  $\mu$ g of total RNA was separated on agarose/formaldehyde gels, and transferred to Zeta-probe membranes (BioRad). The membranes were hybridized initially with an end-labelled oligonucleotide probe specific for CCR5. The blots were stripped and then rehybridized with a random-primed 1.3kb *EcoRI* CXCR4/Fusin gene fragment. The membranes were then stripped and hybridized with an end-labelled oligonucleotide probe specific for 28S ribosomal RNA and the transcripts were visualized using a Molecular Dynamics phosphorimager. The positions of 18S and 28S rRNA are indicated by open arrows, while probe-specific bands are indicated by closed arrows. The image in part (A) was obtained with a 2 hour exposure, the image in part (C) with a 10 minute exposure, while the image in part (B) was obtained with a 48 hour exposure.

09027205-022098

Figure 5 is a depiction of an assay indicating that the natural ligand for CD28 permits infection with CCR5-dependent virus.

Figure 6 is a depiction of an assay indicating that CD3, CD28, and CTLA-4 together are able to block some but not all genes induced by CD28.

5 Figure 7 is a depiction of an assay indicating that susceptibility to HIV-1 can be modulated by varying the ratio of CD28 to CTLA-4.

Figure 8 is a depiction of an assay indicating that CTLA-4 reverses CD28 downregulation of CCR5.

Figure 9 is a depiction of a model indicating that the ratio of CD28 to CTLA-4  
10 expression may be a critical determinant of susceptibility to HIV-1 infection.

### **Detailed Description of the Invention**

This invention pertains to methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as  
15 CD28. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell. In another  
20 embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by allowing stimulation of a CD28-associated signal in the T cell, by, for example, using an agent which blocks the interaction of B7 molecules (e.g., B7-1 and B7-2) with CTLA4, e.g., soluble CTLA4 antibodies or fragments thereof, thereby allowing B7 molecules to interact and stimulate a CD28-associated signal in the T cell.

25 Accordingly, one aspect of the invention pertains to methods for inhibiting or downregulating expression of an HIV-1 fusion cofactor (e.g., CCR5) by stimulating intracellular signal transduction associated with CD28 ligation. In one embodiment, an intracellular signal is stimulated by contacting a T cell expressing a CD28 cell surface receptor, such as a CD4<sup>+</sup> T cell, with an agent which acts extracellularly to stimulate a  
30 CD28-associated signal in the T cell (e.g., a ligand which binds CD28 or CTLA-4) or an agent which acts intracellularly to stimulate a CD28-associated signal in the T cell (e.g., an agent which stimulates production of D-3 phosphoinositides in the T cell, see e.g., PCT/US95/05213). The term "a T cell expressing a cell surface receptor that binds a costimulatory molecule" is intended to encompass T cells expressing CD28 and/or  
35 CTLA4, or other receptor capable of binding a costimulatory molecule such as B7-1, B7-2 or other B7 family member.

In one embodiment, stimulation of the accessory molecule CD28 is accomplished by contacting an activated population of T cells with a ligand which binds CD28. Activation of the T cells with, for example, an anti-CD3 antibody and stimulation of the CD28 accessory molecule results in proliferation of CD4<sup>+</sup> T cells. An anti-CD28 monoclonal antibody or fragment thereof capable of crosslinking the CD28 molecule, or a natural ligand for CD28 (e.g., a member of the B7 family of proteins, such as B7-1 (CD80) and B7-2 (CD86) (Freeman, A.S. et al. (1987) *J. Immunol.* 137:3260-3267; Freeman, G.J. et al. (1989) *J. Immunol.* 143:2714-2722; Freeman, G.J. et al. (1991) *J. Exp. Med.* 174:625-631; Freeman, G.J. et al. (1993) *Science* 262:909-911; Azuma, M. et al. (1993) *Nature* 366:76-79; Freeman, G.J. et al. (1993) *J. Exp. Med.* 178:2185-2192)) can be used to induce stimulation of the CD28 molecule. In addition, binding homologues of a natural ligand, whether native or synthesized by chemical or recombinant technique, can also be used in accordance with the invention. Ligands useful for stimulating an accessory molecule can be used in soluble form, attached to the surface of a cell, or immobilized on a solid phase surface as described herein. Anti-CD28 antibodies or fragments thereof useful in stimulating proliferation of CD4<sup>+</sup> T cells include monoclonal antibody 9.3, an IgG2a antibody (Dr. Jeffery Ledbetter, Bristol Myers Squibb Corporation, Seattle, WA), monoclonal antibody KOLT-2, an IgG1 antibody, 15E8, an IgG1 antibody, 248.23.2, an IgM antibody and EX5.3D10, an IgG2a antibody. In one specific embodiment, the molecule providing the primary activation signal, for example a molecule which provides stimulation through the TCR/CD3 complex or CD2, and the costimulatory molecule are coupled to the same solid phase support. In particular, T cell activation and costimulation can be provided by a solid phase surface containing anti-CD3 and anti-CD28 antibodies.

25 In another embodiment, stimulation of the accessory molecule CD28 is accomplished by contacting an activated population of T cells with a ligand which binds CTLA-4. For example, anti-CTLA4 antibodies that cross react with CD28, e.g., 7G11 mAb, can be used. Such antibodies can be produced by techniques described below. In a preferred embodiment, the anti-CTLA4 antibody binds an epitope on CTLA4 which  
30 includes or encompasses an amino acid sequence:

(Xaa)<sub>n</sub>-Pro-Pro-Tyr-Tyr-Leu-(Xaa)<sub>n</sub> (SEQ ID NO:1),  
wherein Xaa is any amino acid and n = 0-20 (preferably 0-10, more preferably 0-5, even  
more preferably 0-3). This amino acid sequence is part of the binding site for B7-1 on  
the CTLA-4 receptor (as described in Harper K. et al. (1991) *J. Immunol.* 47:1037-  
1044). In native human CTLA4, this sequence is located at amino acid positions 101 to  
105. Xaa can be additional CTLA4 amino acid residues flanking this region or can be  
other residues, e.g., included to enhance solubility or immunogenicity of the peptide. A



peptide containing a common CD28/CTLA4 epitope (e.g., SEQ ID NO:1) can be used as an immunogen to raise an anti-CD28/CTLA4 antibody. The anti-CTLA-4 antibody can prevent the B7-1 and B7-2 ligands from binding to the CTLA-4 receptor, thereby allowing these ligands to bind to the CD28 receptor and stimulate a CD28-associated  
5 signal in the T cell.

In a specific embodiment of the invention, activated T cells are contacted with a stimulatory form of a natural ligand for CD28 for costimulation. The natural ligands of CD28 include the members of the B7 family of proteins, such as B7-1 (CD80) and B7-2 (CD86). B7-1 and B7-2 are collectively referred to herein as "B7 molecules". A  
10 "stimulatory form of a natural ligand for CD28" is a form of a natural ligand that is able to bind to CD28 and costimulate the T cell.

"Costimulation" or a "response" by a T cell is intended to encompass T cell responses that occur upon triggering of a primary activation signal (e.g., stimulation through the CD3/TCR complex or through CD2) and a costimulatory signal in the T cell, and includes lymphokine production (e.g., IL-2 production) and T cell proliferation.  
15 Inhibition of a T cell response may involve complete blocking of the response (i.e., a lack of a response) or a reduction in the magnitude of the response (i.e., partial inhibition of the response).

A primary activation signal in a population of T cells is accomplished by  
20 contacting the T cells with an agent which stimulates a TCR/CD3 complex-associated signal in the T cells. Stimulation of the TCR/CD3 complex-associated signal in a T cell is accomplished either by ligation of the T cell receptor (TCR)/CD3 complex or the CD2 surface protein, or by directly stimulating receptor-coupled signaling pathways. Thus, an anti-CD3 antibody, an anti-CD2 antibody, or a protein kinase C activator in  
25 conjunction with a calcium ionophore is used to activate a population of T cells.

An anti-CD3 monoclonal antibody can be used to provide a primary activation signal to a population of T cells via the TCR/CD3 complex. Although a number of anti-human CD3 monoclonal antibodies are commercially available, OKT3 prepared from hybridoma cells obtained from the American Type Culture Collection or monoclonal  
30 antibody G19-4 is preferred. Similarly, binding of an anti-CD2 antibody will activate T cells. Stimulatory forms of anti-CD2 antibodies are known and available. Stimulation through CD2 with anti-CD2 antibodies is typically accomplished using a combination of at least two different anti-CD2 antibodies. Stimulatory combinations of anti-CD2 antibodies which have been described include the following: the T11.3 antibody in  
35 combination with the T11.1 or T11.2 antibody (Meuer, S.C. et al. (1984) *Cell* 36:897-906) and the 9.6 antibody (which recognizes the same epitope as T11.1) in combination with the 9-1 antibody (Yang, S. Y. et al. (1986) *J. Immunol.* 137:1097-1100). Other

09027205.022098

antibodies which bind to the same epitopes as any of the above described antibodies can also be used. Additional antibodies, or combinations of antibodies, can be prepared and identified by standard techniques.

A primary activation signal can also be delivered to a T cell through use of a combination of a protein kinase C (PKC) activator such as a phorbol ester (e.g., phorbol myristate acetate) and a calcium ionophore (e.g., ionomycin which raises cytoplasmic calcium concentrations). The use of these agents bypasses the TCR/CD3 complex but delivers a stimulatory signal to T cells. These agents are also known to exert a synergistic effect on T cells to promote T cell activation and can be used in the absence of antigen to deliver a primary activation signal to T cells.

The agent providing the primary activation signal and the agent providing the costimulatory agent can be added either in soluble form or coupled to a solid phase surface. In a preferred embodiment, the two agents are coupled to the same solid phase surface.

#### Soluble forms of B7 molecules as costimulator

The natural ligands of CD28 can also be presented to T cells in a soluble form. Soluble forms of B7 molecules include natural B7 molecules (e.g., B7-1, B7-2), a fragment thereof, or modified form of the full length or fragment of the B7 molecule that is able to bind to CD28 and costimulate the T cell. Costimulation can be evidenced by proliferation and/or cytokine production by T cells that have received a primary activation signal. Modifications of B7 molecules include modifications that preferably enhance the affinity of binding of B7 molecules to CD28 molecules, but also modifications that diminish or do not affect the affinity of binding of B7 molecules to CD28 molecules. Modifications of B7 molecules also include those that increase the stability of a soluble form of a B7 molecule. The modifications of B7 molecules are usually produced by amino acid substitutions, but can also be produced by linkage to another molecule.

In one specific embodiment, the soluble form of a B7 molecule is a fusion protein containing a first peptide consisting of a B7 molecule (e.g., B7-1, B7-2), or fragment thereof and a second peptide corresponding to a moiety that alters the solubility, binding, affinity, stability, or valency (i.e., the number of binding sites available per molecule) of the first peptide. Preferably, the first peptide includes an extracellular domain portion of a B7 molecule that interacts with CD28 and is able to provide a costimulatory signal as evidenced by stimulation of proliferation of T cells or secretion of cytokines from the T cells upon exposure to the B7Ig fusion protein and a primary T cell activation signal. Thus, a B7-1Ig fusion protein will comprise at least

09027205-022098

about amino acids 1-208 of B7-1 and a B7-2Ig fusion protein will comprise at least about amino acids 24-245 of B7-2.

The second peptide is a fragment of an Ig molecule, such as an Fc fragment that comprises the hinge, CH2 and CH3 regions of human IgG1 or IgG4. Several Ig fusion proteins have been previously described (see e.g., Capon, D.J. *et al.* (1989) *Nature* 337:525-531 and Capon U.S. Patent 5,116,964 [CD4-IgG1 constructs]; Linsley, P.S. *et al.* (1991) *J. Exp. Med.* 173:721-730 [a CD28-IgG1 construct and a B7-1-IgG1 construct]; and Linsley, P.S. *et al.* (1991) *J. Exp. Med.* 174:561-569 [a CTLA4-IgG1]). A resulting B7Ig fusion protein (e.g., B7-1Ig, B7-2Ig) may have altered B7-2 solubility, binding affinity, stability, or valency and may increase the efficiency of protein purification. In particular fusion of a B7 molecule or portion thereof to the Fc region of an immunoglobulin molecule generally provides an increased stability to the protein, in particular in the plasma.

Fusion proteins within the scope of the invention can be prepared by expression of a nucleic acid encoding the fusion protein in a variety of different systems. Typically, the nucleic acid encoding a B7 fusion protein comprises a first nucleotide sequence encoding a first peptide consisting of a B7 molecule or a fragment thereof and a second nucleotide sequence encoding a second peptide corresponding to a moiety that alters the solubility, binding, stability, or valency of the first peptide, such as an immunoglobulin constant region. Nucleic acid encoding a peptide comprising an immunoglobulin constant region can be obtained from human immunoglobulin mRNA present in B lymphocytes. It is also possible to obtain nucleic acid encoding an immunoglobulin constant region from B cell genomic DNA. For example, DNA encoding C $\gamma$ 1 or C $\gamma$ 4 can be cloned from either a cDNA or a genomic library or by polymerase chain reaction (PCR) amplification in accordance standard protocols. A preferred nucleic acid encoding an immunoglobulin constant region comprises all or a portion of the following: the DNA encoding human C $\gamma$ 1 (Takahashi, N.S. *et al.* (1982) *Cell* 29:671-679), the DNA encoding human C $\gamma$ 2; the DNA encoding human C $\gamma$ 3 (Huck, S., *et al.* (1986) *Nucl. Acid Res.* 14:1779); and the DNA encoding human C $\gamma$ 4. When an immunoglobulin constant region is used in the B7 fusion protein, the constant region can be modified to reduce at least one constant region mediated biological effector function. For example, DNA encoding a C $\gamma$ 1 or C $\gamma$ 4 constant region can be modified by PCR mutagenesis or site directed mutagenesis. Protocols and reagents for site directed mutagenesis systems can be obtained commercially from Amersham International PLC, Amersham, UK.

In a particularly preferred embodiment of the invention, B7-1Ig and B7-2Ig fusion proteins comprise about amino acids 1-208 of B7-1 and about amino acids 24-245 of B7-2, respectively, fused to the heavy chain of IgG1.

In one embodiment the first and second nucleotide sequences are linked (i.e., in a 5' to 3' orientation by phosphodiester bonds) such that the translational frame of the B7 protein or fragment thereof and the IgC (i.e., Fc fragment that comprises the hinge, CH2, and CH3 regions of human IgG) coding segments are maintained (i.e., the nucleotide sequences are joined together in-frame). Thus, expression (i.e., transcription and translation) of the nucleotide sequence produces a functional B7Ig fusion protein. The nucleic acids of the invention can be prepared by standard recombinant DNA techniques. For example, a B7Ig fusion protein can be constructed using separate template DNAs encoding B7 and an immunoglobulin constant region. The appropriate segments of each template DNA can be amplified by polymerase chain reaction (PCR) and ligated in frame using standard techniques. A nucleic acid of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which has been automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071, incorporated by reference herein).

The nucleic acids encoding B7 molecules or B7Ig fusion proteins (e.g., B7-1, B7-2) can be inserted into various expression vectors, which in turn direct the synthesis of the corresponding protein in a variety of hosts, particularly eucaryotic cells, such as mammalian or insect cell culture and procaryotic cells, such as *E. coli*. Expression vectors within the scope of the invention comprise a nucleic acid as described herein and a promoter operably linked to the nucleic acid. Such expression vectors can be used to transfect host cells to thereby produce fusion proteins encoded by nucleic acids as described herein. An expression vector of the invention, as described herein, typically includes nucleotide sequences encoding a B7 molecule or B7Ig fusion protein operably linked to at least one regulatory sequence. "Operably linked" is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence in a host cell (or by a cell extract). Regulatory sequences are art-recognized and can be selected to direct expression of the desired protein in an appropriate host cell. The term regulatory sequence is intended to include promoters, enhancers, polyadenylation signals and other expression control elements. Such regulatory sequences are known to those skilled in the art and are described in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). It should be understood that the design of the expression vector

09027205.022003

may depend on such factors as the choice of the host cell to be transfected and/or the type and/or amount of protein desired to be expressed.

An expression vector of the invention can be used to transfect cells, either procaryotic or eucaryotic (e.g., mammalian, insect or yeast cells) to thereby produce fusion proteins encoded by nucleotide sequences of the vector. Expression in procaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters. Certain *E. coli* expression vectors (so called fusion-vectors) are designed to add a number of amino acid residues to the expressed recombinant protein, usually to the amino terminus of the expressed protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the target recombinant protein; and 3) to aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. Examples of fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia) and pMAL (New England Biolabs, Beverly, MA) which fuse glutathione S-transferase and maltose E binding protein, respectively, to the target recombinant protein. Accordingly, a B7 molecule or B7Ig fusion gene may be linked to additional coding sequences in a procaryotic fusion vector to aid in the expression, solubility or purification of the fusion protein. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the target recombinant protein to enable separation of the target recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

Inducible non-fusion expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector4 relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from the T7 gn10-lac 0 fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident  $\lambda$  prophage harboring a T7 gn1 under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize expression of at B7 molecule or B7Ig fusion protein in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy would be to alter the nucleotide sequence of the B7 molecule or B7Ig fusion protein construct to be inserted into an expression vector so that

the individual codons for each amino acid would be those preferentially utilized in highly expressed *E. coli* proteins (Wada et al., (1992) *Nuc. Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences are encompassed by the invention and can be carried out by standard DNA synthesis techniques.

- Alternatively, a B7 molecule or B7Ig fusion protein can be expressed in a eucaryotic host cell, such as mammalian cells (e.g., Chinese hamster ovary cells (CHO) or NS0 cells), insect cells (e.g., using a baculovirus vector) or yeast cells. Other suitable host cells may be found in Goeddel, (1990) *supra* or are known to those skilled in the art. Eucaryotic, rather than procaryotic, expression of a B7 molecule or B7Ig may be preferable since expression of eucaryotic proteins in eucaryotic cells can lead to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of a recombinant protein. For expression in mammalian cells, the expression vector's control functions are often provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. To express a B7 molecule or B7Ig fusion protein in mammalian cells, generally COS cells (Gluzman, Y., (1981) *Cell* 23:175-182) are used in conjunction with such vectors as pCDM8 (Seed, B., (1987) *Nature* 329:840) for transient amplification/expression, while CHO (dhfr<sup>-</sup> Chinese Hamster Ovary) cells are used with vectors such as pMT2PC (Kaufman et al. (1987), *EMBO J.* 6:187-195) for stable amplification/expression in mammalian cells. A preferred cell line for production of recombinant protein is the NS0 myeloma cell line available from the ECACC (catalog #85110503) and described in Galfre, G. and Milstein, C. ((1981) *Methods in Enzymology* 73(13):3-46; and *Preparation of Monoclonal Antibodies: Strategies and Procedures*, Academic Press, N.Y., N.Y). Examples of vectors suitable for expression of recombinant proteins in yeast (e.g., *S. cerevisiae*) include pYepSec1 (Baldari, et al., (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al., (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith et al., (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow, V.A., and Summers, M.D., (1989) *Virology* 170:31-39).

- Vector DNA can be introduced into procaryotic or eucaryotic cells via conventional transformation or transfection techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming host cells can be found in Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

00027205.02008

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate DNA into their genomes. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker may be introduced into a host cell on the same plasmid as the gene of interest or may be introduced on a separate plasmid. Cells containing the gene of interest can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die). The surviving cells can then be screened for production of B7 molecules or B7Ig fusion proteins by, for example, immunoprecipitation from cell supernatant with an anti-B7 monoclonal antibody.

B7 molecules or B7 Ig fusion proteins produced by recombinant technique may be secreted and isolated from a mixture of cells and medium containing the protein. Alternatively, the protein may be retained cytoplasmically and the cells harvested, lysed and the protein isolated. A cell culture typically includes host cells, media and other byproducts. Suitable mediums for cell culture are well known in the art. Protein can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins.

For T cell costimulation, the soluble forms of the natural ligands for CD28 are added to the T cell culture in an amount sufficient to result in costimulation of activated T cells. The appropriate amount of soluble ligand to be added will vary with the specific ligand, but can be determined by assaying different amounts of the soluble ligand in T cell cultures and measuring the extent of costimulation by proliferation assays or production of cytokines, as described in the Examples.

#### Coupling of the natural ligands to a solid phase surface

In another embodiment of the invention, a natural ligand of CD28 (B7-1, B7-2) can be presented to T cells in a form attached to a solid phase surface, such as beads. The B7 molecules, fragments thereof or modified forms thereof capable of binding to CD28 and costimulating the T cells (e.g., B7 fusion proteins) can be prepared as described for the soluble B7 forms. These molecules can then be attached to the solid phase surface via several methods. For example the B7 molecules can be crosslinked to the beads via covalent modification using tosyl linkage. In this method, B7 molecules or B7 fusion proteins are in 0.05M borate buffer, pH 9.5 and added to tosyl activated magnetic immunobeads (Dynal Inc., Great Neck, NY) according to manufacturer's

instructions. After a 24 hr incubation at 22°C, the beads are collected and washed extensively. It is not mandatory that immunomagnetic beads be used, as other methods are also satisfactory. For example, the B7 molecules may also be immobilized on polystyrene beads or culture vessel surfaces. Covalent binding of the B7 molecules or B7Ig fusion proteins to the solid phase surface is preferable to adsorption or capture by a secondary monoclonal antibody. B7Ig fusion proteins can be attached to the solid phase surface through anti-human IgG molecules bound to the solid phase surface. In particular, beads to which anti-human IgG molecules are bound can be obtained from Advanced Magnetics, Inc. These beads can then be incubated with the B7Ig fusion proteins in an appropriate buffer such as PBS for about an hour at 5°C, and the uncoupled B7Ig proteins removed by washing the beads in a buffer, such as PBS.

It is also possible to attach the B7 molecules to the solid phase surface through an avidin- or streptavidin-biotin complex. In this particular embodiment, the soluble B7 molecule is first crosslinked to biotin and then reacted with the solid phase surface to which avidin or streptavidin molecules are bound. It is also possible to crosslink the B7 molecules with avidin or streptavidin and to react these with a solid phase surface that is covered with biotin molecules.

The amount of B7 molecules attached to the solid phase surface can be determined by FACS analysis if the solid phase surface is that of beads or by ELISA if the solid phase surface is that of a tissue culture dish. Antibodies reactive with the B7 molecules, such as mAb BBI, mAb IT2, and mAb 133 can be used in these assays. Alternatively, CTLA4Ig can also be used for that purpose.

In a specific embodiment, the stimulatory form of a B7 molecule is attached to the same solid phase surface as the agent that stimulates the TCR/CD3 complex, such as an anti-CD3 antibody. In addition to anti-CD3, other antibodies that bind to receptors that mimic antigen signals may be used, for example, the beads or other solid phase surface may be coated with combinations of anti-CD2 and a B7 molecule. The two stimulatory molecules can be bound to the solid phase surface in various ratios, but preferably in equimolar amounts.

#### Production of Antibodies and Coupling of Antibodies to Solid Phase Surfaces

The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as CD3, CD28. Structurally, the simplest naturally occurring antibody (e.g., IgG) comprises four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. It has been shown that the antigen-binding function of an

09027005.02009



antibody can be performed by fragments of a naturally-occurring antibody. Thus, these antigen-binding fragments are also intended to be designated by the term "antibody".

Examples of binding fragments encompassed within the term antibody include (i) an Fab fragment consisting of the VL, VH, CL and CH1 domains; (ii) an Fd fragment consisting of the VH and CH1 domains; (iii) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (iv) a dAb fragment (Ward et al., (1989) *Nature* 341:544-546) which consists of a VH domain; (v) an isolated complementarity determining region (CDR); and (vi) an F(ab')<sub>2</sub> fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region. Furthermore, although the two domains of the Fv fragment are coded for by separate genes, a synthetic linker can be made that enables them to be made as a single protein chain (known as single chain Fv (scFv); Bird et al. (1988) *Science* 242:423-426; and Huston et al. (1988) *PNAS* 85:5879-5883) by recombinant methods. Such single chain antibodies are also encompassed within the term "antibody". Preferred antibody fragments for use in T cell expansion are those which are capable of crosslinking their target antigen, e.g., bivalent fragments such as F(ab')<sub>2</sub> fragments. Alternatively, an antibody fragment which does not itself crosslink its target antigen (e.g., a Fab fragment) can be used in conjunction with a secondary antibody which serves to crosslink the antibody fragment, thereby crosslinking the target antigen. Antibodies can be fragmented using conventional techniques as described herein and the fragments screened for utility in the same manner as described for whole antibodies. An antibody of the invention is further intended to include bispecific and chimeric molecules having a desired binding portion (e.g., CD28 or CTLA-4).

The language "a desired binding specificity for an epitope", as well as the more general language "an antigen binding site which specifically binds (immunoreacts with)", refers to the ability of individual antibodies to specifically immunoreact with a T cell surface molecule, e.g., CD28 or CTLA-4. That is, it refers to a non-random binding reaction between an antibody molecule and an antigenic determinant of the T cell surface molecule. The desired binding specificity is typically determined from the reference point of the ability of the antibody to differentially bind the T cell surface molecule and an unrelated antigen, and therefore distinguish between two different antigens, particularly where the two antigens have unique epitopes. An antibody which binds specifically to a particular epitope is referred to as a "specific antibody".

"Antibody combining site", as used herein, refers to that structural portion of an antibody molecule comprised of a heavy and light chain variable and hypervariable regions that specifically binds (immunoreacts with) antigen. The term "immunoreact" or "reactive with" in its various forms is used herein to refer to binding between an

09027205.022098

antigenic determinant-containing molecule and a molecule containing an antibody combining site such as a whole antibody molecule or a portion thereof.

Although soluble forms of antibodies may be used to activate T cells, it is preferred that the anti-CD3 antibody be immobilized on a solid phase surface (e.g., beads). An antibody can be immobilized directly or indirectly by, for example, by a secondary antibody, to a solid surface, such as a tissue culture flask or bead.

### Specific Methodology for Antibody Production

#### A. The Immunogen.

The term "immunogen" is used herein to describe a composition containing a peptide or protein as an active ingredient used for the preparation of antibodies against an antigen, e.g., a CD3, a CD28, or a CTLA-4 antigen. When a peptide or protein is used to induce antibodies it is to be understood that the peptide can be used alone, or linked to a carrier as a conjugate, or as a peptide polymer.

To generate suitable antibodies, the immunogen should contain an effective, immunogenic amount of a peptide or protein, optionally as a conjugate linked to a carrier. The effective amount of peptide per unit dose depends, among other things, on the species of animal inoculated, the body weight of the animal and the chosen immunization regimen as is well known in the art. The immunogen preparation will typically contain peptide concentrations of about 10 micrograms to about 500 milligrams per immunization dose, preferably about 50 micrograms to about 50 milligrams per dose. An immunization preparation can also include an adjuvant as part of the diluent. Adjuvants such as complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA) and alum are materials well known in the art, and are available commercially from several sources.

Those skilled in the art will appreciate that, instead of using natural occurring forms of the antigen, e.g., the CD3, the CD28, or the CTLA-4 antigen for immunization, synthetic peptides can alternatively be employed towards which antibodies can be raised for use in this invention. Both soluble and membrane bound forms of the protein or peptide fragments are suitable for use as an immunogen and can also be isolated by immunoaffinity purification as well. A purified form of protein, such as may be isolated as described above or as known in the art, can itself be directly used as an immunogen, or alternatively, can be linked to a suitable carrier protein by conventional techniques, including by chemical coupling means as well as by genetic engineering using a cloned gene of the protein. The purified protein can also be covalently or noncovalently modified with non-proteinaceous materials such as lipids or carbohydrates to enhance immunogenicity or solubility. Alternatively, a purified protein can be coupled with or

00027205-02098

incorporated into a viral particle, a replicating virus, or other microorganism in order to enhance immunogenicity. The protein may be, for example, chemically attached to the viral particle or microorganism or an immunogenic portion thereof.

In an illustrative embodiment, a purified CD28 protein, or a peptide fragment thereof (e.g., produced by limited proteolysis or recombinant DNA techniques) is conjugated to a carrier which is immunogenic in animals. Preferred carriers include proteins such as albumins, serum proteins (e.g., globulins and lipoproteins), and polyamino acids. Examples of useful proteins include bovine serum albumin, rabbit serum albumin, thyroglobulin, keyhole limpet hemocyanin, egg ovalbumin and bovine gamma-globulins. Synthetic polyamino acids such as polylysine or polyarginine are also useful carriers. With respect to the covalent attachment of CD28 protein or peptide fragments to a suitable immunogenic carrier, there are a number of chemical cross-linking agents that are known to those skilled in the art. Preferred cross-linking agents are heterobifunctional cross-linkers, which can be used to link proteins in a stepwise manner. A wide variety of heterobifunctional cross-linkers are known in the art, including succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS); N-succinimidyl 4-iodoacetyl aminobenzoate (SIAB), succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC); 4-succinimidyl-oxycarbonyl-a-methyl-a-(2-pyridyldithio)-toluene (SMPT), N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), succinimidyl 6-[3-(2-pyridyldithio) propionate] hexanoate (LC-SPDP).

It may also be desirable to simply immunize an animal with whole cells which express a protein of interest (e.g., CD28, or CTLA-4) on their surface. Various cell lines can be used as immunogens to generate monoclonal antibodies to an antigen, including, but not limited to T cells. For example, peripheral blood T cells can be obtained from a subject which constitutively expresses CD28 or CTLA-4, but can be activated *in vitro* with anti-CD3 antibodies, PHA or PMA. Alternatively, an antigen specific (e.g., alloreactive) T cell clone can be activated to express CD28 or CTLA-4 by presentation of antigen, together with a costimulatory signal, to the T cell. Whole cells that can be used as immunogens to produce CD28 or CTLA-4 specific antibodies also include recombinant transfectants. For example, COS and CHO cells can be reconstituted by transfection with a CD28 or CTLA-4 cDNA to produce cells expressing CD28 or CTLA-4 on their surface. These transfectant cells can then be used as immunogens to produce anti-CD28 or anti-CTLA-4 antibodies. Other examples of transfectant cells are known, particularly eukaryotic cells able to glycosylate the CD28 protein, but any

000027-005-002099

5

Polyclonal antibodies to a purified protein or peptide fragment thereof can generally be raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of an appropriate immunogen, such as the extracellular domain of the protein, and an adjuvant. A polyclonal antisera can be produced, for example, as described in Lindsten, T. et al. (1993) *J. Immunol.* 151:3489-3499. In an illustrative embodiment, animals are typically immunized against the immunogenic protein, peptide or derivative by combining about 1mg to 1 mg of protein with Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of immunogen in Freund's complete adjuvant (or other suitable adjuvant) by subcutaneous injection at multiple sites. Seven to 14 days later, the animals are bled and the serum is assayed for anti-protein or peptide titer (e.g., by ELISA). Animals are boosted until the titer plateaus. Also, aggregating agents such as alum can be used to enhance the immune response.

2

The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of an antigen. A monoclonal antibody composition thus typically displays a single binding affinity for

3

a particular protein with which it immunoreacts. Preferably, the monoclonal antibody used in the subject method is further characterized as immunoreacting with a protein derived from humans.

Monoclonal antibodies useful in the methods of the invention are directed to an epitope of an antigen(s) on T cells, such that complex formation between the antibody and the antigen (also referred to herein as ligation) induces stimulation and T cell expansion. A monoclonal antibody to an epitope of an antigen (e.g., CD3, CD28, or CTLA-4) can be prepared by using a technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975, *Nature* 256:495-497), and the more recent human B cell hybridoma technique (Kozbor et al. (1983) *Immunol Today* 4:72), EBV-hybridoma technique (Cole et al. (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96), and trioma techniques. Other methods which can effectively yield monoclonal antibodies useful in the present invention include phage display techniques (Marks et al. (1992) *J. Biol. Chem.* 16007-16010).

In one embodiment, the antibody preparation applied in the subject method is a monoclonal antibody produced by a hybridoma cell line. Hybridoma fusion techniques were first introduced by Kohler and Milstein (Kohler et al. *Nature* (1975) 256:495-97; Brown et al. (1981) *J. Immunol* 127:539-46; Brown et al. (1980) *J Biol Chem* 255:4980-83; Yeh et al. (1976) *PNAS* 76:2927-31; and Yeh et al. (1982) *Int. J. Cancer* 29:269-75). Thus, the monoclonal antibody compositions of the present invention can be produced by the following method, which comprises the steps of:

(a) Immunizing an animal with a protein (e.g., CD28 or CTLA-4) or peptide thereof. The immunization is typically accomplished by administering the immunogen to an immunologically competent mammal in an immunologically effective amount, i.e., an amount sufficient to produce an immune response. Preferably, the mammal is a rodent such as a rabbit, rat or mouse. The mammal is then maintained for a time period sufficient for the mammal to produce cells secreting antibody molecules that immunoreact with the immunogen. Such immunoreaction is detected by screening the antibody molecules so produced for immunoreactivity with a preparation of the immunogen protein. Optionally, it may be desired to screen the antibody molecules with a preparation of the protein in the form in which it is to be detected by the antibody molecules in an assay, e.g., a membrane-associated form of the antigen, e.g., the CD28 or the CTLA-4 antigen. These screening methods are well known to those of skill in the art, e.g., enzyme-linked immunosorbent assay (ELISA) and/or flow cytometry.

(b) A suspension of antibody-producing cells removed from each immunized mammal secreting the desired antibody is then prepared. After a sufficient time, the mouse is sacrificed and somatic antibody-producing lymphocytes are obtained. Antibody-producing cells may be derived from the lymph nodes, spleens and peripheral blood of primed animals. Spleen cells are preferred, and can be mechanically separated into individual cells in a physiologically tolerable medium using methods well known in the art. Mouse lymphocytes give a higher percentage of stable fusions with the mouse myelomas described below. Rat, rabbit and frog somatic cells can also be used. The spleen cell chromosomes encoding desired immunoglobulins are immortalized by fusing the spleen cells with myeloma cells, generally in the presence of a fusing agent such as polyethylene glycol (PEG). Any of a number of myeloma cell lines may be used as a fusion partner according to standard techniques; for example, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from the American Type Culture Collection (ATCC), Rockville, Md.

The resulting cells, which include the desired hybridomas, are then grown in a selective medium, such as HAT medium, in which unfused parental myeloma or lymphocyte cells eventually die. Only the hybridoma cells survive and can be grown under limiting dilution conditions to obtain isolated clones. The supernatants of the hybridomas are screened for the presence of antibody of the desired specificity, e.g., by immunoassay techniques using the antigen that has been used for immunization. Positive clones can then be subcloned under limiting dilution conditions and the monoclonal antibody produced can be isolated. Various conventional methods exist for isolation and purification of the monoclonal antibodies so as to free them from other proteins and other contaminants. Commonly used methods for purifying monoclonal antibodies include ammonium sulfate precipitation, ion exchange chromatography, and affinity chromatography (see, e.g., Zola et al. in *Monoclonal Hybridoma Antibodies: Techniques And Applications*, Hurell (ed.) pp. 51-52 (CRC Press 1982)). Hybridomas produced according to these methods can be propagated *in vitro* or *in vivo* (in ascites fluid) using techniques known in the art.

Generally, the individual cell line may be propagated *in vitro*, for example in laboratory culture vessels, and the culture medium containing high concentrations of a single specific monoclonal antibody can be harvested by decantation, filtration or centrifugation. Alternatively, the yield of monoclonal antibody can be enhanced by injecting a sample of the hybridoma into a histocompatible animal of the type used to provide the somatic and myeloma cells for the original fusion. Tumors secreting the specific monoclonal antibody produced by the fused cell hybrid develop in the injected animal. The body fluids of the animal, such as ascites fluid or serum, provide

00027205.022098

monoclonal antibodies in high concentrations. When human hybridomas or EBV-hybridomas are used, it is necessary to avoid rejection of the xenograft injected into animals such as mice. Immunodeficient or nude mice may be used or the hybridoma may be passaged first into irradiated nude mice as a solid subcutaneous tumor, cultured *in vitro* and then injected intraperitoneally into pristane primed, irradiated nude mice which develop ascites tumors secreting large amounts of specific human monoclonal antibodies.

Media and animals useful for the preparation of these compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al. (1959) *Virol.* 8:396) supplemented with 4.5 gm/1 glucose, 20 mM glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

#### D. Combinatorial Antibodies.

Monoclonal antibody compositions of the invention can also be produced by other methods well known to those skilled in the art of recombinant DNA technology. An alternative method, referred to as the "combinatorial antibody display" method, has been developed to identify and isolate antibody fragments having a particular antigen specificity, and can be utilized to produce monoclonal antibodies (for descriptions of combinatorial antibody display see e.g., Sastry et al. (1989) *PNAS* 86:5728; Huse et al. (1989) *Science* 246:1275; and Orlandi et al. (1989) *PNAS* 86:3833). After immunizing an animal with an appropriate immunogen (e.g., CD3, CD28) as described above, the antibody repertoire of the resulting B-cell pool is cloned. Methods are generally known for directly obtaining the DNA sequence of the variable regions of a diverse population of immunoglobulin molecules by using a mixture of oligomer primers and PCR. For instance, mixed oligonucleotide primers corresponding to the 5' leader (signal peptide) sequences and/or framework 1 (FR1) sequences, as well as primer to a conserved 3' constant region primer can be used for PCR amplification of the heavy and light chain variable regions from a number of murine antibodies (Larrick et al. (1991) *Biotechniques* 11:152-156). A similar strategy can also be used to amplify human heavy and light chain variable regions from human antibodies (Larrick et al. (1991) *Methods: Companion to Methods in Enzymology* 2:106-110).

In an illustrative embodiment, RNA is isolated from activated B cells of, for example, peripheral blood cells, bone marrow, or spleen preparations, using standard protocols (e.g., U.S. Patent No. 4,683,202; Orlandi, et al. *PNAS* (1989) 86:3833-3837; Sastry et al., *PNAS* (1989) 86:5728-5732; and Huse et al. (1989) *Science* 246:1275-

09067205.022098





separable based on antigen affinity. Isolated scFV antibodies immunoreactive with the antigen can subsequently be formulated into a pharmaceutical preparation for use in the subject method.

Once displayed on the surface of a display package (e.g., filamentous phage), the antibody library is screened with the protein, or peptide fragment thereof, to identify and isolate packages that express an antibody having specificity for the protein. Nucleic acid encoding the selected antibody can be recovered from the display package (e.g., from the phage genome) and subcloned into other expression vectors by standard recombinant DNA techniques.

#### E. Hybridomas and Methods of Preparation.

Hybridomas useful in the present invention are those characterized as having the capacity to produce a monoclonal antibody which will specifically immunoreact with an antigen of interest, e.g., a CD3, a CD28, or a CTLA-4 antigen. Methods for generating hybridomas that produce, e.g., secrete, antibody molecules having a desired immunospecificity, e.g., having the ability to immunoreact with the CD28 or CTLA-4 antigen, and/or an identifiable epitope of CD28 or CTLA-4 are known in the art. Particularly applicable is the hybridoma technology described by Niman et al. (1983) *PNAS* 80:4949-4953; and by Galfre et al. (1981) *Meth. Enzymol.* 73:3-46.

#### F. Chimeric and Humanized anti-CD28 or anti-CTLA4 Antibodies.

When antibodies produced in non-human subjects are used therapeutically in humans, they are recognized to varying degrees as foreign and an immune response may be generated in the patient. One approach for minimizing or eliminating this problem, which is preferable to general immunosuppression, is to produce chimeric antibody derivatives, i.e., antibody molecules that combine a non-human animal variable region and a human constant region. Such antibodies are the equivalents of the monoclonal and polyclonal antibodies described above, but may be less immunogenic when administered to humans, and therefore more likely to be tolerated by the patient.

Chimeric mouse-human monoclonal antibodies (i.e., chimeric antibodies) reactive with CD28 or CTLA4 can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the constant region of a murine (or other species) anti-CD28 or anti-CTLA4 antibody molecule is substituted with a gene encoding a human constant region (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., PCT Application WO 86/01533; Cabilly et al. U.S. Patent No.

09027205.022098

- 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 *Science* 240:1041-1043); Liu et al. (1987) *PNAS* 84:3439-3443; Liu et al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *PNAS* 84:214-218; Nishimura et al. (1987) *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl Cancer Inst.* 80:1553-1559).

A chimeric antibody can be further "humanized" by replacing portions of the variable region not involved in antigen binding with equivalent portions from human variable regions. General reviews of "humanized" chimeric antibodies are provided by Morrison, S. L. (1985) *Science* 229:1202-1207 and by Oi et al. (1986) *BioTechniques* 4:214. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of an immunoglobulin variable region from at least one of a heavy or light chain. Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from an anti-CD28 or anti-CTLA4 antibody producing hybridoma. The cDNA encoding the chimeric antibody, or fragment thereof, can then be cloned into an appropriate expression vector. Suitable "humanized" antibodies can be alternatively produced by CDR or CEA substitution (see U.S. Patent 5,225,539 to Winter; Jones et al. (1986) *Nature* 321:552-525; Verhoeven et al. (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060).

As an alternative to humanizing an mAb from a mouse or other species, a human mAb directed against a human protein can be generated. Transgenic mice carrying human antibody repertoires have been created which can be immunized with human CD28 or CTLA4. Splenocytes from these immunized transgenic mice can then be used to create hybridomas that secrete human mAbs specifically reactive with human CD28 or CTLA4 (see, e.g., Wood et al. PCT publication WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. PCT publication WO 92/03918; Kay et al. PCT publication 92/03917; Lonberg, N. et al. (1994) *Nature* 368:856-859; Green, L.L. et al. (1994) *Nature Genet.* 7:13-21; Morrison, S.L. et al. (1994) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. (1993) *Year Immunol* 7:33-40; Tuailon et al. (1993) *PNAS* 90:3720-3724; Bruggeman et al. (1991) *Eur. J. Immunol.* 21:1323-1326).

#### Agents which act intracellularly to stimulate a signal associated with CD28 ligation

In another embodiment of the invention, a CD28-associated signal is provided by contacting T cells with an agent which acts intracellularly to stimulate a signal in the T cell mediated by ligation of CD28. The term "agent", as used herein, is intended to encompass chemicals and other pharmaceutical compounds which stimulate a costimulatory or other signal in a T cell without the requirement for an interaction between a T cell surface receptor and a costimulatory molecule or other ligand. For

00027005-022098

example, the agent may act intracellularly to stimulate a signal associated with CD28 ligation. In one embodiment, the agent is a non-proteinaceous compound. As the agent used in the method is intended to bypass the natural receptor:ligand stimulatory mechanism, the term agent is not intended to include a cell expressing a natural ligand.

- 5 Natural ligands for CD28 include members of the B7 family of proteins, such as B7-1(CD80) and B7-2 (CD86).

It is known that CD28 receptor stimulation leads to the production of D-3 phosphoinositides in T cells and that inhibition of the activity of phosphatidylinositol 3-kinase (PI3K) in a T cell can inhibit T cell responses, such as lymphokine production and cellular proliferation. Protein tyrosine phosphorylation has also been shown to occur in T cells upon CD28 ligation and it has been demonstrated that a protein tyrosine kinase inhibitor, herbimycin A, can inhibit CD28-induced IL-2 production (Vandenberghe, P. et al. (1992) *J. Exp. Med.* 175:951-960; Lu, Y. et al. (1992) *J. Immunol.* 149:24-29). Thus, the CD28 receptor mediated pathway can be stimulated by contacting T cells with an activator of PI3K or an agent which stimulates protein tyrosine phosphorylation in the T cell, or both. An activator of PI3K can be identified based upon its ability to stimulate production of at least one D-3 phosphoinositide in a T cell. The term "D-3 phosphoinositide" is intended to include derivatives of phosphatidylinositol that are phosphorylated at the D-3 position of the inositol ring and encompasses the compounds phosphatidylinositol(3)-monophosphate (PtdIns(3)P), phosphatidylinositol(3,4)-bisphosphate (PtdIns(3,4)P<sub>2</sub>), and phosphatidylinositol(3,4,5)-trisphosphate (PtdIns(3,4,5)P<sub>3</sub>). Thus, in the presence of a PI3K activator, the amount of a D-3 phosphoinositide in the T cell is increased relative to the amount of the D-3 phosphoinositide in the T cell in the absence of the substance. Production of D-3 phosphoinositides (e.g., PtdIns(3)P, PtdIns(3,4)P<sub>2</sub> and/or PtdIns(3,4,5)P<sub>3</sub>) in a T cell can be assessed by standard methods, such as high pressure liquid chromatography or thin layer chromatography, as discussed above. Similarly, protein tyrosine phosphorylation can be stimulated in a T cell, for example, by contacting the T cell with an activator of protein tyrosine kinases, such as pervanadate (see O'Shea, J.J. et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10306-10310; and Secrist, J.P. (1993) *J. Biol. Chem.* 268:5886-5893). Alternatively, the T cell can be contacted with an agent which inhibits the activity of a cellular protein tyrosine phosphatase, such as CD45, to increase the net amount of protein tyrosine phosphorylation in the T cell.

### 35 Uses of the Invention

An individual infected with HIV can be treated *in vivo* or *ex vivo* by contacting T cells of the individual with an agent which stimulates (e.g., anti-CD28 antibody) or

00027205.022000

allows stimulation of (e.g., soluble anti-CTLA4 antibody or fragment thereof) a CD28-associated signal in the T cell, thereby downregulating an HIV-1 fusion cofactor, such as CCR5. The agent which provides a primary activation signal can be administered to the individual, or it can be an agent which is already in the individual, such as one or more antigens.

The invention further provides methods for vaccination of an individual against infection by HIV. Accordingly, in one embodiment of the invention, an agent which downregulates expression of an HIV-1 fusion cofactor by stimulating or allowing stimulation of a CD28-associated signal, such as an immobilized anti-CD28 or anti-CTLA-4 antibody, is administered to an individual prior to a viral infection. The method can further comprise administration to the individual of an agent which provides a primary activation signal to the T cells (e.g., an anti-CD3 antibody).

The invention is particularly useful for treating subjects suffering from chronic HIV-1 infection. Stimulation of the CD28 receptor leads to an upregulation of  $\beta$ -chemokines, such as RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$  (described in, for example, Reily, J.L. et al. (1997) *J. Immunol.* 158:5545-53). The increased secretion of these chemokines can, in turn, benefit neighboring cells by preventing further infection. Thus, the method of the invention can further be used to upregulate  $\beta$ -chemokines, thereby inhibiting HIV infection of bystander cells.

In other preferred embodiments, the agent which stimulates or allows stimulation of a CD28-associated signal to thereby downregulate an HIV-1 fusion cofactor, e.g., CCR5, can be coadministered with another treatment. For example, the agent can be coadministered with an influenza vaccine. Preferred agents for use in this embodiment are anti-CTLA-4 antibodies (preferably soluble) or fragments thereof (preferably Fab fragments) which inhibit binding of B7 molecules to CTLA4, but allow B7 molecules, such as B7 molecules on antigen-presenting cells, to provide costimulation to T cells via CD28 crosslinking, in the context of presentation of viral antigen (such anti-CTLA4 antibodies and fragments thereof are described in, for example, Krummel, M.F. et al. (1995) *Int. Immunol.* 8(4):519-23).

#### Compositions and Kits

This invention also provides compositions and kits comprising an agent which stimulates or allows stimulation of an accessory molecule on the surface of T cells (e.g., an anti-CD28 or an anti-CTLA-4 antibody) coupled to a solid phase surface in an amount sufficient to down regulate expression of an HIV-1 fusion cofactor (e.g., CCR5), and, optionally, including an agent which stimulates a TCR/CD3 complex-associated signal in T cells (e.g., an anti-CD3 antibody) coupled to the same or different solid phase

surface. For example, the composition can comprise an anti-CD28 and an anti-CD3 antibody coupled to the same solid phase surface (e.g., a bead). Alternatively, the composition can include an agent which stimulates an accessory molecule on the surface of T cells coupled to a first solid phase surface and an agent which stimulates a TCR/CD3 complex-associated signal in T cells coupled to a second solid phase surface. For example, the composition can include an anti-CD28 coupled to a first bead and an anti-CD3 antibody coupled to a second bead. Another embodiment of the invention provides compositions including an effective amount of an anti-CTLA-4 antibody (preferably in soluble form) or a fragment thereof (e.g., a Fab fragment). Kits comprising such compositions and instructions for use are also within the scope of this invention.

#### Methods for Identifying Agents Which Modulate Expression of an HIV-1 Fusion Cofactor

Another aspect of the invention pertains to screening assays for identifying inhibitors and activators of expression of an HIV-1 fusion cofactor, such as CCR5, in a cell following stimulation or inhibition of one or more intracellular signals which result from ligation of a surface receptor on the cell which binds a costimulatory molecule, such as CD28. In one embodiment, a T cell which expresses a cell surface receptor (e.g., CD28 or CTLA-4) which binds a costimulatory molecule is utilized. To identify an inhibitor of expression of an HIV-1 fusion cofactor, such as CCR5, an intracellular signal transduction pathway associated with the receptor in the T cell (e.g., CD28) is stimulated in the presence of an agent to be tested and an inhibitor is identified based upon its ability inhibit or downregulate expression of the HIV-1 fusion cofactor in the T cell.

A costimulatory signal can be stimulated in the T cell by contacting the T cell with a ligand for CD28 or CTLA-4. The ligand can be a physiologic ligand, such as membrane-bound B7-1 or B7-2, or an antibody directed against the T cell surface receptor. A cell which naturally expresses B7-1 and/or B7-2 can be used or more preferably a cell (e.g., a CHO cell) which is transfected to express a costimulatory molecule is used. In the presence of an inhibitor, stimulation of a T cell through a surface receptor which binds a costimulatory molecule (e.g., CD28) results in downregulation or a reduction in the levels of CCR5 RNA in the T cell relative to stimulation in the absence of the inhibitor. RNA levels in the T cell can be measured by any suitable method known in the art, such as those described in the Examples section. For example, RNA expression (e.g., CCR5 RNA) can be detected using Northern blots, *in situ* hybridization, or RNA-based polymerase chain reaction. Alternatively, a specific

protein product can be detected by Western blot. Preferably, the detection technique will be quantitative or at least semi-quantitative.

In one embodiment, mRNA is obtained from a sample of cells, and transcripts encoding an HIV-1 fusion cofactor are detected. To illustrate, an initial crude cell suspension, such as may be obtained from dispersion of a sample, is sonicated or otherwise treated to disrupt cell membranes so that a crude cell extract is obtained. Known techniques of biochemistry (e.g., preferential precipitation of proteins) can be used for initial purification if desired. The crude cell extract, or a partially purified RNA portion therefrom, is then treated to further separate the RNA. For example, crude cell extract can be layered on top of a 5 ml cushion of 5.7 M CsCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA in a 1 in. x 3 1/2 in. nitrocellulose tube and centrifuged in an SW27 rotor (Beckman Instruments Corp., Fullerton, CA) at 27,000 rpm for 16 hrs at 15°C. After centrifugation, the tube contents are decanted, the tube is drained, and the bottom 0.5 cm containing the clear RNA pellet is cut off with a razor blade. The pellets are transferred to a flask and dissolved in 20 ml 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 5% sarcosyl and 5% phenol. The solution is then made 0.1 M in NaCl and shaken with 40 ml of a 1:1 phenol:chloroform mixture. RNA is precipitated from the aqueous phase with ethanol in the presence of 0.2 M Na-acetate pH 5.5 and collected by centrifugation. Any other method of isolating RNA from a cellular source may be used instead of this method. Other mRNA isolation protocols, such as the Chomczynski method (described in U.S. Patent No. 4,843,155), are known in the art.

The mRNA must be isolated from the source cells under conditions which preclude degradation of the mRNA. The action of RNase enzymes is particularly to be avoided because these enzymes are capable of hydrolytic cleavage of the RNA nucleotide sequence. A suitable method for inhibiting RNase during extraction from cells involves the use of 4 M guanidium thiocyanate and 1 M mercaptoethanol during the cell disruption step. In addition, a low temperature and a pH near 5.0 are helpful in further reducing RNase degradation of the isolated RNA.

In certain embodiments, the next step may be to form DNA complementary to the isolated heterogeneous sequences of mRNA. The enzyme of choice for this reaction is reverse transcriptase, although in principle any enzyme capable of forming a faithful complementary DNA copy of the mRNA template could be used. The cDNA transcripts produced by the reverse transcriptase reaction are somewhat heterogeneous with respect to sequences at the 5' end and the 3' end due to variations in the initiation and termination points of individual transcripts, relative to the mRNA template. The variability at the 5' end is thought to be due to the fact that the oligo-dT primer used to initiate synthesis is capable of binding at a variety of loci along the polyadenylated

09027205.022096

region of the mRNA. Synthesis of the cDNA transcript begins at an indeterminate point in the poly-A region, and variable length of poly-A region is transcribed depending on the initial binding site of the oligo-dT primer. It is possible to avoid this indeterminacy by the use of a primer containing, in addition to an oligo-dT tract, one or two nucleotides of the RNA sequence itself, thereby producing a primer which will have a preferred and defined binding site for initiating the transcription reaction.

In an exemplary embodiment, there is provided a nucleic acid composition comprising a (purified) oligonucleotide probe including a region of nucleotide sequence which is capable of hybridizing to a sense or antisense sequence of an HIV-1 fusion cofactor (e.g., CCR5) transcript. The nucleic acid of a cell is rendered accessible for hybridization, the probe is exposed to nucleic acid of the sample, and the hybridization of the probe to the sample nucleic acid is detected. Such techniques can be used to quantitatively determine mRNA transcript levels.

In certain embodiments, detection of the such transcripts utilizes a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1944) *PNAS* 91:360-364). In an illustrative embodiment, the method includes the steps of (i) collecting a sample of cells from a patient, (ii) isolating nucleic acid (e.g., mRNA) from the cells of the sample, (iii) contacting the nucleic acid sample (or optionally a cDNA preparation derived therefrom) with one or more primers which specifically hybridize to a CCR5 transcript, for example, under conditions such that hybridization and amplification of at least a portion of the transcript (if present) occurs, and (iv) detecting the presence or absence of an amplification product.

Detection and/or amplification can be carried out with a probe which, for example, hybridizes under stringent conditions to a nucleic acid encoding the transcript of interest. For detection, the probe preferably further comprises a label group attached to the nucleic acid and able to be detected.

In yet another embodiment, the assay detects the presence or absence of an HIV-1 fusion cofactor (e.g., CCR5) in cells of the cell sample, e.g., by determining the level of the protein by an immunoassay, gel electrophoresis or the like.

This invention is further illustrated by the following Examples which should not be construed as limiting. The contents of all references and published patent applications cited throughout this application are hereby incorporated by reference. The following methodology described in the Materials and Methods section was used throughout the examples set forth below.

## EXAMPLES

### **Materials and Methods**

#### Antibodies and Reagents

- 5       The following monoclonal antibodies were used to stimulate cells: anti-CD3  
OKT3 (mouse IgG2a, American Type Tissue Collection), anti-CD28 9.3 (mouse IgG2a,  
(Hansen, J. A., 1980. Immunogenetics 10:247), anti-CD2 35.1 (mouse IgG2a, American  
Type Tissue Collection), anti-CD4 G17-2 (mouse IgG1, (Ledbetter, J. A., 1987. Mol.  
Immunol. 24:1255)), anti-CD5 10.2 (mouse IgG2a, (Martin, P. J., 1980.  
10 Immunogenetics 1 1:429)), and anti-monomorphic HLA class I mAb W6/32 (IgG2a,  
American Type Tissue Collection).

#### Cell Separation and Stimulation

- Peripheral blood lymphocytes were isolated by Percoll gradient centrifugation  
15 from leukopacks obtained by apheresis of healthy donors. CD4+ T cells were purified  
by negative selection as described previously (June, C. H., 1987 *Mol. Cell Biol.* 7:4472).  
The purity of the CD4 cells was monitored after each apheresis. The cell preparations  
were 88 to 98% pure for CD4 cells, and were found to contain less than 5 % CD8 cells.  
CD8 cells were purified in a similar manner with the addition of a positive selection step  
20 using Dynal Detach-A-Bead®. (Dynal, Great Neck, NY).

- Purified cells were cultured at  $1 \times 10^6$  cells/ml in RPMI with 10% FCS (Hyclone,  
Logan, UT), 20mM HEPES, 2mM glutamine, 50µg/ml of gentamicin (Biofluids,  
Rockville, MD). Cells were stimulated with either 5µg/ml of PHA (Sigma, St. Louis,  
MI) and 100 units of IL-2 (Boehringer Mannheim, Indianapolis, IN) or Dynal M-450  
25 antibody coated beads using 1 bead per cell (Dynal, Great Neck, NY). Magnetic  
polystyrene beads were coated via tosyl conjugation (Levine, B. L., (1996) *Science*  
272:1939) with equal amounts of anti-CD3 plus anti-CD28 monoclonal antibody, anti-  
CD3 plus anti-CD2 monoclonal antibody, anti-CD3 plus anti-CD4 monoclonal antibody,  
anti-CD3 plus anti-CD5 monoclonal antibody or anti-CD3 plus anti-MHC I monoclonal  
30 antibody. The cell cultures were fed every 2-3 days with fresh medium to maintain a  
concentration of  $1 \times 10^6$  cells/ml.

- Conditioned medium was collected from companion cultures of autologous cells  
that were set up in parallel and not infected with HIV-1. The conditioned medium was  
subjected to centrifugation, and the supernatant was added to a 50% final concentration.  
35 In some experiments, NABs to C-C chemokines were added to the conditioned medium  
as described above.



### Acute infection procedure

In order to further dissect the mechanisms of the CD28 antiviral effect, we have developed a quantitative acute infection system measuring virus and cells to study antiviral effects. Purified peripheral blood CD4 cells were activated by various mitogenic stimulants. In all experiments presented herein, flow cytometric analysis of the cell populations revealed <5% contamination with CD8 cells. Macrophage-tropic strains of HIV-1 were used to infect purified CD4 cells. Viral stocks were prepared exclusively by passage on PBMC. Viral growth was quantitated by assay for HIV-1 *gag* as previously described (Levine, B. L., (1996) *Science* 272:1939). Cell growth was quantitated by enumeration of cells and cell volume. IL-2 was added to the culture medium in all conditions to assure similar cellular growth rates. To address specificity of the CD28 effect, polystyrene beads were coated with anti-CD3 mAb OKT3 to deliver a signal through the T cell receptor. Costimulatory signals were provided by preparing beads coated with equivalent amounts of anti-CD28 mAb 9.3. Cells were pelleted and washed with RPMI with 10% FCS and the supernatant (CM) was saved. Cells were infected in a 0.4 ml volume containing 50% appropriate CM and approximately  $1 \times 10^4$  TCID<sub>50</sub> DNase-treated HIV-1<sub>US-1</sub> (Mascola, J. R., 1994 *J. Infect. Dis.* 169:48) or HIV-1<sub>Ba-L</sub> (Gartner, S. (1986) *Science* 233:215) was added. After 2 hours at 37°C, the cell/virus mixture was washed 3 times with RPMI + 10% FCS to remove residual inoculum and the cells were refed with 50% CM to a concentration of  $1 \times 10^6$  cells/ml. After 3 days, the cells were counted and sized again and refed with either RPMI with 10% FCS or 50% CM, if the experiment warranted that a heterologous CM be maintained in the culture, to a concentration of  $1 \times 10^6$ /ml.  $1 \times 10^6$  cells were removed from the cultures at the various time points mentioned in the figure legends and pelleted and the supernatants were saved for p24 analysis. The cell pellets were washed once with HBSS and frozen.

### PCR \ Liquid Hybridization assay

A quantitative PCR was used to measure HIV-1 proviral DNA. The assay is sensitive to about 5 copies per  $10^5$  cells (Levine, B. L. (1996) *Science* 272:1939). Frozen cell pellets containing  $1 \times 10^6$  cells were resuspended in 100:1 lysis buffer [10 mM Tris-HCl, (pH7.5), 2.5 mM MgCl<sub>2</sub>, 0.45% Triton X-100 (Boehringer Mannheim), 0.45% Tween 20 (Biorad), and 0.12mg/ml proteinase K (Boehringer Mannheim)]. HIV-1 *gag* DNA sequences were amplified from crude lysates as described (Levine, B. L. (1996) *Science* 272:1939). The amplified products were detected by liquid hybridization with end-labelled oligonucleotide probes, followed by gel electrophoresis. PCR products were quantitated as described (Levine, B. L. et al.) using a Molecular

00027205, 022095

Dynamics phosphorimager. Copy number was determined by comparison to plasmid standards and data presented was found to be linear to 10,000 copies of *gag*. To standardize cell pellets, human  $\beta$ -globin sequences were amplified from a 1/20 dilution of the crude lysates as described (Vahey, M. T. 1995. Quantitative Liquid Hybridization PCR Method Employing Storage Phosphor Technology. In PCR Primer: A Laboratory Manual. C.W. Dieffenbach and G.S. Dveksler, eds. Cold Spring Harbor Laboratory Press, p. 313).

#### Chemokine, lymphokine, and p24 assays

Using appropriate dilutions of culture supernatants, MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, IFN- $\gamma$ , and p24 were assayed with R&D Systems (Minneapolis, MN), Endogen (Cambridge, MA), and Coulter (Kendall, FL) ELISA kits according to the manufacturer's instructions.

### **EXAMPLE 1: Production and Screening of Anti-CTLA4 Monoclonal Antibodies**

#### Production of Monoclonal Antibodies to human CTLA4

Balb/c female mice (obtained from Taconic, Germantown, NY) can be immunized subcutaneously and intraperitoneally with either 50 mg per mouse of recombinant human *E. coli*-expressed CTLA4 (extracellular domain only) emulsified in complete Freund's adjuvant (Sigma Chemical Company, St. Louis, MO) for ER series mice or  $2 \times 10^6$  PMA/ionomycin-activated human T cells (obtained from Leukopaks) per mouse for ES series mice. The mice can then be boosted with 20-25 mg/mouse human recombinant CTLA4 emulsified in incomplete Freund's adjuvant (Sigma Chemical Company, St. Louis, MO) or  $10^6$  PMA/ionomycin-activated human T cells at 14 day intervals following the initial immunizations. The mice are bled from the tail vein and the sera assayed for the presence of antibodies reactive to the immunogen by ELISA against the immunizing protein. Mice showing a strong serological titre are boosted intravenously with 50 mg recombinant human CTLA4 per mouse diluted in phosphate-buffered saline, pH 7.2 (GIBCO, Grand Island, NY). Three to four days following the boost, the spleens from these mice are fused at a 5:1 ratio with SP 2/0-Ag 14 myeloma cells (ATCC, Rockville, MD) with PEG 1450 (ATCC, Rockville, MD) and plated onto 96 well plates containing irradiated MRC-5 fibroblast cells (ATCC, Rockville, MD) in Dulbecco's modified Eagle's media (GIBCO, Grand Island, NY) containing 25 % CPSR-3 (Sigma Chemical Company), 2 mM L-glutamine, 50 U/ml

09027205, 022008

penicillin, 50 mg/ml streptomycin, 20 mg/ml gentamycin, 0.25 mg/ml fungizone, and 10 % NCTC-109 (GIBCO, Grand Island, NY). Selection of hybridomas can be done in the presence of hypoxanthineaminopterin-thymidine (ATCC, Rockville, MD). As hybridoma colonies grow out in the next 10-21 days, supernatant from the wells is screened on 96 well flat-bottomed EIA plates (Costar, Cambridge, MA) coated with recombinant human CTLA4 as a primary screen. Secondary screening is done by flow cytometry on human CTLA4-transfected CHO cells and PMA/ionomycin activated human T cells. Hybridoma supernatants identified as containing antibodies directed towards CTLA4 are expanded and subcloned twice prior to ascites production and antibody purification by Protein A-Sepharose affinity chromatography.

#### Primary Screening of mAbs: ELISA Protocol

Each well of a 96 well flat bottomed EIA plate (Costar, Cambridge, MA) can be coated with 50 µl per well of a 1 mg/ml recombinant human CTLA4 solution made in phosphate-buffered saline, pH 7.2, overnight at 4° C. The CTLA4 solution is aspirated off and the wells were blocked with 100 µl of 1% BSA in phosphate-buffered saline, pH 7.2 for 1 hour at room temperature. Following this blocking incubation, the wells are washed 3X with phosphate-buffered saline, pH 7.2 and 50 µl hybridoma supernatant is added per well and incubated 45 minutes at 37° C. Following this incubation, the wells are washed 3X with phosphate-buffered saline, pH 7.2 and then incubated with 50 µl per well of a 1:4000 dilution of horseradish peroxidase-conjugated affinity purified Goat anti-Mouse IgG (H&L) specific antibodies (Zymed Laboratories, San Francisco, CA) for 45 minutes at 37° C. The wells are then washed 3 X with phosphate-buffered saline, pH 7.2 followed by a 30 minute incubation in 50 µl per well of 1 mM ABTS (2,2 azino-bis-3-ethylbenzthiazole-6-sulfonic acid) in 0.1 M sodium citrate, pH 4.2, to which a 1:1000 dilution of 30 % hydrogen peroxide has been added as a substrate for the HRP to detect bound antibody. The absorbance is then determined at 410 nm on a spectrophotometer (Molecular Devices Corp, Menlo Park, CA).

#### Secondary Screening of mAbs: Flow Cytometry

Secondary screening can be done by flow cytometry on human CTLA4-gpi-transfected CHO cells and PMA/ionomycin activated human T cells. CTLA4 is expressed on CHO and COS cells by linking the extracellular domain of CTLA4 to a glycosylphosphatidylinositol (gpi) anchor. DNA encoding the extracellular domain of CTLA4 can be amplified from a human CTLA4 cDNA by PCR using as sense primer, CATGAAGCTTCTCGAGCCGCCACCAT GGCTTGCCCTTGA (SEQ ID NO: 2), containing a Hind III site, a strong translational start site, and the first 15 nucleotides of

00027205.022098

the CTLA4 coding sequence and an antisense primer,  
 GAGAATTCTAGACTAGCTTAAGTCAGAATCTGGGCACGGT (SEQ ID NO: 3),  
 containing the last 19 nucleotides of the CTLA4 extracellular domain and an Afl II site.  
 PCR conditions were 94°, 1 min, 43°, 1 min, 72°, 1 min for 35 cycles followed by one  
 cycle of 72° for 10 min. The PCR product can be digested with Hind III and Afl II, gel  
 purified, and ligated into a Hind III and Afl II digested pCDM8 vector containing the gpi  
 anchor of human CD58 (see *J. Immunol.* 148:3271, kindly provided by Dr. Donald  
 Staunton, Center for Blood Research, Boston, MA). Plasmid containing the CTLA4-gpi  
 insert are transiently transfected into COS cells and strongly expressed cell surface  
 CTLA4, as judged by binding of B7-Ig fusion protein. The CTLA4-gpi plasmid is  
 cotransfected into CHO cells with a plasmid encoding neomycin resistance and stable  
 transfectants are selected with G418. CHO cell transfectants are sorted on the basis of  
 B7-Ig binding and cloned.

Cells for flow cytometry (either CHO-CTLA4 or activated human T cells) are  
 washed thoroughly in 1% BSA in phosphate-buffered saline, pH 7.2, then incubated  
 with 50 ml hybridoma supernatant or culture media per 10<sup>6</sup> cells for 30 minutes at 4° C.  
 Following the incubation, the cells are washed 3 X with 1 % BSA in phosphate-buffered  
 saline, pH 7.2, then incubated in 50 ml of a 1:40 dilution of fluorescein conjugated Goat  
 anti-Mouse IgG (H&L) antibodies (Zymed Laboratories, San Francisco, CA) for 30  
 minutes at 4° C. The cells are then washed 3 X in 1 % BSA in phosphate-buffered  
 saline, pH 7.2 and fixed in 1 % paraformaldehyde solution. The cell samples are then  
 analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA).

## **EXAMPLE 2: Characterization of Anti-CTLA4 Monoclonal Antibodies**

### **Binding Specificity**

To determine the binding specificity of the CTLA-4 mAbs, their binding to either  
 CHO cells transfected to express CD28 or CHO cells transfected to express CTLA-4 is  
 assessed by indirect immunofluorescence. The binding pattern of the different anti-  
 CTLA4 mAbs is then compared to a control, e.g., anti-CD28 mAb 3D10.

## **EXAMPLE 3: The CD28 antiviral effect is restricted to M-tropic isolates of HIV-1**

Purified CD4<sup>+</sup> lymphocytes were obtained from uninfected donors as described  
 in, for example, C. H. June et al. (1987) *Mol. Cell. Biol.* 7:4472, and B. L. Levine et al.  
 (1995) *Int. Immunol.* 7:891 (1995). The purified cells were stimulated with DYNAL

M-450 beads coated via tosyl conjugation with equal quantities of  $\alpha$ CD3 (OKT3, mouse IgG2a, American Type Tissue Collection), and  $\alpha$ CD28 (9.3, mouse IgG2a) (4). Alternatively, purified CD4<sup>+</sup> cells were stimulated with phytohemagglutinin [PHA, 5  $\mu$ g/ml (Sigma)] and 100 units/ml IL-2 (Boehringer Mannheim). Three days after stimulation, 7 x 10<sup>6</sup> CD4 cells stimulated with  $\alpha$ CD3/ $\alpha$ CD28 (open symbols; Figure 1) or PHA/IL-2 (filled symbols; Figure 1) were infected with 1 x 10<sup>4</sup> TCID<sub>50</sub> (median tissue culture infectious dose) of HIV<sub>US1</sub> (squares; Figure1) or with 1 x 10<sup>4</sup> MAGI (described in, for example, J. Kimpton, et al. (1992) *J. Virol.* 66:2232) infectious doses of HIV<sub>NL4-3</sub> (circles; Figure1). After 2 hours at 37°C, the cells were washed three times and refed with 50% conditioned medium to a final concentration of 1 x 10<sup>6</sup> cells/ml. At the designated time points, cleared supernatant was analyzed for the presence of p24<sub>Gag</sub> antigen by ELISA (Coulter). Each experiment was done at least 5 times, and representative values are depicted.

As shown in Figure1, the CD28 antiviral effect is restricted to M-tropic isolates of HIV-1. Incubation of PHA/IL-2-activated CD4<sup>+</sup> cells with either HIV<sub>US1</sub> or HIV<sub>NL4-3</sub> resulted in a productive infection. When CD3/CD28-activated CD4 cells were infected with HIV<sub>US1</sub>, p24<sub>Gag</sub> antigen production was virtually undetectable throughout the experiment, in agreement with a previous observation that CD3/CD28-activated cells are resistant to infection with the M-tropic isolate HIV<sub>Ba-L</sub> (described in B. L. Levine et al.). However, when CD3/CD28-stimulated cells were infected with the TCL-tropic isolate HIV<sub>NL4-3</sub>, a productive infection ensued (Figure1).

**EXAMPLE 4: Only cells stimulated with immobilized  $\alpha$ CD3/ $\alpha$ CD28 are resistant to infection with the M-tropic isolate**

**HIV-1<sub>Ba-L</sub>**

CD28-mediated resistance to M-tropic viruses requires costimulation with bead-immobilized  $\alpha$ CD28 because stimulation of CD4<sup>+</sup> cells with bead-immobilized  $\alpha$ CD3 and soluble  $\alpha$ CD28, or with bead-immobilized  $\alpha$ CD3 and IL-2, renders the cells sensitive to infection with M-tropic viruses. To further investigate the specificity of the CD28-mediated antiviral effect, beads were prepared containing antibodies to CD3 in combination with antibodies to the cell surface coreceptors CD2, CD4, CD5, CD7 and MHC Class I. Binding of antibodies to these coreceptors in conjunction with  $\alpha$ CD3 treatment increases cellular proliferation. Purified CD4 cells were stimulated with beads coated with  $\alpha$ CD3 and antibodies to the various surface receptors. IL-2 was added to all cultures to ensure that all combinations of immobilized antibodies resulted in equivalent cell proliferation.

As shown in Figure 2, purified CD4<sup>+</sup> cells were stimulated with either PHA and IL-2 (lanes 1-4), or with beads coated with equal quantities of  $\alpha$ CD3/ $\alpha$ CD28 (lanes 5-8),  $\alpha$ CD3/ $\alpha$ MHC class I (lanes 9-12),  $\alpha$ CD3/ $\alpha$ CD2 (lanes 13-16),  $\alpha$ CD3/ $\alpha$ CD4 (lanes 17-20),  $\alpha$ CD3/ $\alpha$ CD5 (lanes 21-24) and  $\alpha$ CD3/ $\alpha$ CD7 (lanes 25-28). Three days post-stimulation, 5 x 10<sup>6</sup> CD4<sup>+</sup> cells stimulated by each method were infected with 10<sup>4</sup> TCID<sub>50</sub> (median tissue culture infectious dose) of HIV<sub>Ba-L</sub>. 1 x 10<sup>6</sup> cells were harvested immediately after virus addition (hour 0), post-virus washout (hour 2), and at designated time points thereafter. HIV-1 *gag* DNA sequences present in crude cell lysates were quantitated using a previously described PCR-based assay (19).

Quantitative results are shown (9). All exposures were for one hour.

The results shown in Figure 2 demonstrate that only cells stimulated with immobilized  $\alpha$ CD3/ $\alpha$ CD28 were resistant to infection with the M-tropic isolate HIV-1<sub>Ba-L</sub> (Figure2). Quantitative analysis indicated that the resistance was robust.

**EXAMPLE 5: Early events in the viral replication cycle confirm that the CD28 antiviral effect is restricted to M-tropic viruses**

To determine the nature of the M-tropic-specific block, early events in the viral replication cycle were examined by monitoring reverse transcription in HIV-1-infected CD3/CD28- and PHA/IL-2-stimulated CD4 cells (Figure3). Purified CD4<sup>+</sup> cells were stimulated with PHA/IL-2 (left panels) or  $\alpha$ CD3/ $\alpha$ CD28 (right panels) as described in Figure1. Three days after stimulation, 5 x 10<sup>6</sup> cells were infected with 1 x 10<sup>4</sup> TCID<sub>50</sub> of the M-tropic isolates HIV<sub>US1</sub> and HIV<sub>Ba-L</sub> or 1 x 10<sup>4</sup> MAGI infectious doses of the TCL-tropic isolate HIV<sub>NL4-3</sub>, as described in Figure1. Virus stocks were treated with DNase (Boehringer Mannheim) prior to harvesting to degrade contaminating viral DNA. Cells were harvested immediately after infection (lanes marked 0), as well as 2, 6, 12, 24, and 72 hours after infection, as indicated in the figure. HIV DNA was detected as described in Figure2. Early reverse transcription (strong stop) products were amplified using the following primers: 5'-GGC TAA CTA GGG AAC CCA CTG-3' (sense, SEQ ID NO:4) and 5'-CTG CTA GAG ATT TTC CAC ACT GAC -3' (antisense, SEQ ID NO:5). Products were detected by liquid hybridization with an end-labelled oligonucleotide probe (5'-CCG TCT GTT GTG TGA CTC TGG TAA CTA GAG-3', SEQ ID NO:6). The small amount of strong stop DNA present in time zero samples most likely represents reverse transcription products initiated within the virion. Input cell equivalents were standardized by amplification of human  $\beta$ -globin DNA sequences. Amplified  $\beta$ -globin DNA sequences are shown immediately underneath the HIV DNA panels.

03027205.02008

As shown in Figure 3, in PHA/IL-2-treated cells, strong stop DNA was detectable shortly after infection with all three viruses, and the level increased for the duration of the experiment. Furthermore, in CD3/CD28-stimulated cells infected with HIV<sub>NL4-3</sub>, strong stop DNA products accumulated rapidly, confirming that the CD28 antiviral effect was restricted to M-tropic viruses. In contrast, little or no strong stop DNA was detected in  $\alpha$ CD3/ $\alpha$ CD28-treated cells infected with either HIV<sub>Ba-L</sub> or HIV<sub>US1</sub>.

**EXAMPLE 6:**                    **The block in the ability of M-tropic viruses to enter CD3/CD28-stimulated cells is at the level of envelope-mediated membrane fusion**

The failure of M-tropic HIV-1 isolates to initiate reverse transcription in CD3/CD28-stimulated CD4<sup>+</sup> cells suggested that a prior event in the replication cycle, such as viral binding or entry, was impaired. Since CD3/CD28-stimulated cells and PHA/IL-2-stimulated cells express equivalent levels of surface CD4, the ability of activated CD4<sup>+</sup> T cells to support membrane fusion by envelope glycoproteins from different viral isolates was analyzed using a  $\beta$ -galactosidase reporter gene-based cell fusion assay (as described in, for example, C. C. Broder et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:9004; and O. Nussbaum, C. C. et al. (1994) *J. Virol.* 68:5411). PHA/IL-2-stimulated CD4 cells fused with cells expressing either TCL-tropic or M-tropic HIV-1 envelopes. In contrast, whereas CD3/CD28-activated cells fused efficiently with cells expressing TCL-tropic envelopes, they failed to fuse with cells expressing M-tropic envelopes. This experiment demonstrated that the block in the ability of M-tropic viruses to enter CD3/CD28-stimulated cells was at the level of envelope-mediated membrane fusion. The high level to which CD3/CD28-stimulated cells fused with cells expressing the LAV envelope is consistent with the susceptibility of CD3/CD28-activated cells to infection by TCL-tropic isolates.

**EXAMPLE 7:**                    **No CCR5 transcripts are detected at any point in CD3/CD28-stimulated cells**

In this experiment, expression of the HIV-1 fusion cofactors CXCR4/Fusin and CCR5 for TCL-tropic and M-tropic HIV-1 isolates respectively was examined in CD4<sup>+</sup> cells stimulated with PHA/IL-2 or  $\alpha$ CD3/ $\alpha$ CD28 by assaying for transcripts encoding these chemokine receptors (Figure 4). RNA was isolated from  $5 \times 10^7$  unstimulated CD4<sup>+</sup> cells (lane 1) or from CD4 cells stimulated with PHA/IL-2 (lanes 2 and 3) or  $\alpha$

09027205.022098

CD3/ $\alpha$ CD28 (lanes 4 and 5) at the indicated times post-stimulation using RNAsat (Teltest). 20  $\mu$ g of total RNA was separated on agarose/formaldehyde gels, and transferred to Zeta-probe membranes (BioRad). The membranes were hybridized initially with an end-labelled oligonucleotide probe specific for CCR5 (5'-CTT GAT AAT CCA TCT TGT TCC ACC CTG TGC-3' SEQ ID NO:7). The sequence of the CCR5-specific oligonucleotide probe was chosen to distinguish between CCR5 and the closely related transcripts encoding CCR2A and CCR2B. The blots were stripped and then rehybridized with a random-primed 1.3kb *EcoRI* CXCR4/Fusin gene fragment (described in B. Federspiel et al., (1993) *Genomics* 16:707; H. Herzog, Y. et al. (1993) *Cell. Biol.* 12:465; E. E. Jazin et al., (1993) *Regul. Pept.* 47: 247; P. Loetscher et al., (1994) *J. Biol. Chem.* 269:232; H. Nomura, B. et al. (1993) *Int. Immunol.* 5:1239). The membranes were then stripped and hybridized with an end-labelled oligonucleotide probe specific for 28S ribosomal RNA (Clontech), to ensure that equivalent amounts of RNA were loaded in each lane. Transcripts were visualized using a Molecular Dynamics phosphorimager. The positions of 18S and 28S rRNA are indicated by open arrows, while probe-specific bands are indicated by closed arrows. The image in part (A) was obtained with a 2 hour exposure, the image in part (C) with a 10 minute exposure, while the image in part (B) was obtained with a 48 hour exposure.

As shown in Figure 4, CXCR4/Fusin transcripts (1.8 kb) were detected at low abundance in unstimulated CD4<sup>+</sup> cells, and stimulation with either  $\alpha$ CD3/ $\alpha$ CD28 or PHA/IL-2 induced a rapid increase in CXCR4/Fusin transcript levels (Figure 4). Transcripts encoding CCR5 were not detected in unstimulated cells. Although 4.0 kb CCR5-specific transcripts were detected shortly after PHA/IL-2 stimulation of CD4<sup>+</sup> cells, no CCR5 transcripts were detected at any point in CD3/CD28-stimulated cells.

#### **EXAMPLE 8: Mechanism Which Accounts for the CD28 Antiviral Effect**

In this example, the mechanism that accounts for the CD28 antiviral effect was studied. Using the methods described above, it was first shown that a natural ligand for CD28, e.g., B7-1, permits infection with CCR5-dependent virus (see Figure 5). The hypothesis that B7 stimulated cells were susceptible to M-tropic HIV-1 infection because of B7-1's interaction with CTLA-4, was then studied. To do this, anti-CTLA-4 antibodies were immobilized on beads with varying amounts of anti-CD28 antibodies. The ability of these beads to mimic B7-1 stimulation was investigated using the methods described above. The results indicate that the susceptibility to HIV-1 can be modulated by varying the ratio of CD28 to CTLA-4 (bound on the bead) (see Figure 7) and that



bound CTLA-4 reverses CD28 downregulation of CCR5 (see Figure 8) and blocks  $\beta$ -chemokine production.

Therefore, as indicated in Figure 9, a signal through the CD28 receptor leads to downregulation of CCR5 expression and decreased susceptibility to HIV-1 infection, and a signal through the CTLA-4 receptor leads to upregulation of CCR5 expression and increased susceptibility to HIV-1 infection.

The above described results in experiments #3-7 indicate that the susceptibility of CD3/CD28-stimulated cells to TCL-tropic viruses results from upregulation of CXCR-4/Fusin mRNA expression, consistent with the high level of fusion between CD3/CD28-stimulated cells and cells expressing TCL-tropic envelope glycoproteins. Furthermore, the resistance of CD3/CD28-activated cells to infection by M-tropic viruses and primary isolates of HIV-1 correlates with the absence of detectable CCR5 mRNA expression. This is consistent with the inability of CD3/CD28-stimulated cells to fuse with cells expressing M-tropic envelope glycoproteins.

Although the mechanism by which CCR5 expression is inhibited in CD3/CD28-stimulated CD4 cells is unknown, CD28 costimulation exerts many effects on gene expression in general and cytokine expression in particular. CD28-induced down regulation of  $\beta$ -chemokine receptors may be a general feature in T cells, as Loetscher and colleagues recently reported that costimulation of CD4<sup>+</sup> cells with  $\alpha$ CD3/CD28 induced the down regulation of CCR1 and CCR2. In recent studies we have found that CD3/CD28-stimulated CD4 cells produced high levels of  $\beta$ -chemokines in comparison to lectin-stimulated cells, and that the levels are similar to cells stimulated with a variety of costimuli such as CD3/CD5. Thus, high levels of  $\beta$ -chemokines are not sufficient to mediate down regulation of CCR5. Together, these results indicate that chemokine receptor expression is regulated by distinct forms of T cell activation and that chemokine receptor expression is not a consequence of T cell activation in general.

The progression to AIDS is associated with a shift from an M-tropic to a TCL-tropic viral phenotype. Although the selective forces driving this phenotypic transition are not well defined, T cell activation itself could be a selective force. CD3/CD28-stimulated CD4<sup>+</sup> cells may exert selective pressure in favor of TCL-tropic isolate production through the combination of high levels of  $\beta$ -chemokine production and lack of CCR5 expression. Presumably antigen/B7 stimulated CD4 T cells have a similar M-tropic resistance phenotype. At least early in infection, selective forces other than the susceptibility phenotype of CD4<sup>+</sup> target cells may be dominant, as individuals who are homozygous for a defective allele of CCR5 remain resistant to infection and heterozygotes are suggested to have a delayed progression of infection. These findings

09027205.022006

may have important consequences for immune reconstitution or gene therapy initiatives in HIV-infected individuals.

Stimulation of cells with immobilized antibodies to CD3 and CD28 permits the large scale ex vivo expansion of primary CD4<sup>+</sup> cells, thus removing one of the largest  
5 obstacles to gene therapy or immune replacement therapy for HIV-1-infected individuals. Indeed, persistent increased CD4 counts and a lack of spikes in viral load has been noted in a clinical trial that is currently in progress to test the CD28 antiviral effect in patients with intermediate stage HIV infection. The work presented herein demonstrates that lymphocyte proliferation and HIV-1 fusion cofactor expression can be  
10 unlinked.

#### EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than  
15 routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

09027205-022008

- 41 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Carl H. June et al.
- (ii) TITLE OF INVENTION: Methods for Modulating Expression of an  
HIV-1 Fusion Cofactor
- 10 (iii) NUMBER OF SEQUENCES: 7
- (iv) CORRESPONDENCE ADDRESS:
- 15 (A) ADDRESSEE: LAHIVE & COCKFIELD, LLP  
(B) STREET: 28 State Street  
(C) CITY: Boston  
(D) STATE: Massachusetts  
(E) COUNTRY: USA  
(F) ZIP: 02109
- 20 (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:  
(B) FILING DATE:  
30 (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: US 60/037,422  
(B) FILING DATE: 21-FEB-1997
- 35 (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Amy E. Mandragouras  
(B) REGISTRATION NUMBER: 36,207  
(C) REFERENCE/DOCKET NUMBER: GIN-005
- 40 (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (617) 227-7400  
(B) TELEFAX: (617) 742-4214
- 45 (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
- 50 (A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- 55 (v) FRAGMENT TYPE: internal

09027205.022095

- 42 -

## (ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 1

5 (D) OTHER INFORMATION: /note= "Xaa is bewteen 0 and 20  
amino acids"

## (ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION: 7

10 (D) OTHER INFORMATION: /note= "Xaa is between 0 and 20  
amino acids"

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Xaa Pro Pro Tyr Tyr Leu Xaa  
1 5

20 (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

25 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CATGAAGCTT CTCGAGCCGC CACCATGGCT TGCCTTGGA

39

35

(2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 base pairs

40 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

50 GAGAATTCTA GACTAGCTTA AGTCAGAATC TGGGCACGGT

40

(2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

55 (A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

- 43 -

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

10 GGCTAAGTAG GGAACCCACT G  
21

(2) INFORMATION FOR SEQ ID NO:5:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: cDNA

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTGCTAGAGA TTTTCACAC TGAC

24

(2) INFORMATION FOR SEQ ID NO:6:

30

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: cDNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCGTCTGTTG TGTGACTCTG GTAACCTAGAG  
30

45

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

55

0007205.0200

- 44 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTTGATAATC CATCTTGTTT CACCCTGTGC

30

850220:502/2060

## CLAIMS:

1. A method for modulating HIV-1 fusion cofactor expression, comprising manipulating an accessory molecule on the surface of a T cell, thereby modulating HIV-1 fusion cofactor expression.
2. The method of claim 1, wherein said accessory molecule on the surface of a T cell is a CD28 molecule.
3. The method of claim 1, wherein said accessory molecule on the surface of a T cell is a CTLA-4 molecule.
4. The method of claim 1, wherein said HIV-1 fusion cofactor is CCR5.
5. The method of claim 1, wherein said HIV-1 fusion cofactor expression is down regulated.
6. The method of claim 5, wherein said HIV-1 fusion cofactor expression is down regulated by stimulating a CD28-associated signal in the T cell.
7. The method of claim 6, wherein said CD28-associated signal is an intracellular signal.
8. The method of claim 1, wherein said HIV-1 fusion cofactor expression is up regulated.
9. The method of claim 8, wherein said HIV-1 fusion cofactor expression is up regulated by inhibiting a CD28-associated signal in the T cell.
10. The method of claim 9, wherein said CD28-associated signal is an intracellular signal.
11. The method of claim 1, wherein said HIV-1 fusion cofactor expression is modulated *in vivo*.
12. The method of claim 1, wherein said HIV-1 fusion cofactor expression is modulated *in vitro*.

13. The method of claim 1, wherein said accessory molecule on the surface of said T cell is manipulated by the use of an agent which interacts with said accessory molecule.

5

14. The method of claim 13, wherein said agent is an antibody.

15. The method of claim 14, wherein said antibody is an anti-CD28 antibody.

10 16. The method of claim 14, wherein said antibody is an anti-CTLA-4 antibody or fragment thereof.

17. The method of claim 16, wherein said anti-CTLA-4 antibody binds an epitope on the CTLA-4 molecule comprising the B7-1 or B7-2 binding site.

15

18. The method of claim 13, wherein said agent is a combination of an anti-CD28 and an anti-CD3 antibody.

19. The method of claim 13, wherein said agent is a combination of an anti-CD28 and an anti-CD3 antibody, immobilized on a solid surface.

20

20. The method of claim 16, wherein said anti-CTLA-4 antibody is soluble.

21. A method for treating a subject having an HIV-1 infection, comprising administering to said subject an agent which stimulates a CD28-associated signal in the T cells of said subject, thereby treating said subject having an HIV-1 infection.

25

22. The method of claim 21, wherein said agent is an antibody.

30 23. The method of claim 22, wherein said antibody is an anti-CD28 antibody.

24. The method of claim 22, wherein said antibody is an anti-CTLA-4 antibody.

35 25. The method of claim 24, wherein said anti-CTLA-4 antibody binds an epitope on the CTLA-4 molecule comprising the B7-1 or B7-2 binding site.

00027205, 022098



26. The method of claim 21, wherein said agent is a combination of an anti-CD28 and an anti-CD3 antibody.

27. The method of claim 21, wherein said agent is a combination of an anti-  
5 CD28 and an anti-CD3 antibody, immobilized on a solid surface.

28. The method of claim 24, wherein said anti-CTLA-4 antibody is soluble.

29. The method of claim 21, wherein said agent is co-administered with an  
10 influenza vaccine.

30. The method of claim 21, wherein said subject is suffering from chronic HIV-1 infection.

31. The method of claim 21, further comprising determining the levels of  
15 CCR5 expression in said subject.

32. The method of claim 21, further comprising determining the level of viral  
load in said subject.

33. A method for treating a subject having an HIV-1 infection, comprising:  
obtaining T cells from said subject; and  
contacting said T cells with an agent which stimulates a CD28-associated  
signal in said T cells of said subject, thereby treating said subject having an HIV-  
1 infection.  
25

34. The method of claim 33, wherein said agent is an antibody.

35. The method of claim 34, wherein said antibody is an anti-CD28 antibody.  
30

36. The method of claim 34, wherein said antibody is an anti-CTLA-4  
antibody or fragment thereof.

37. The method of claim 36, wherein said anti-CTLA-4 antibody binds an  
35 epitope on the CTLA-4 molecule comprising the B7-1 or B7-2 binding site.

00027205.022099

38. The method of claim 33, wherein said agent is a combination of an anti-CD28 and an anti-CD3 antibody.

39. The method of claim 33, wherein said agent is a combination of an anti-  
5 CD28 and an anti-CD3 antibody, immobilized on a solid surface.

40. The method of claim 36, wherein said anti-CTLA-4 antibody is soluble.

41. The method of claim 33, further comprising determining the levels of  
10 CCR5 expression in said T cells.

42. The method of claim 33, further comprising determining the levels of viral load in said T cells.

43. A composition for treating HIV comprising an effective amount of an  
15 agent which downregulates an HIV-1 fusion cofactor expression.

44. The composition of claim 43, wherein said agent is coupled to a solid  
phase surface.

45. The composition of claim 43, wherein said agent is an antibody.  
20

46. The composition of claim 45, wherein said antibody is an anti-CD28  
antibody.

47. The composition of claim 45, wherein said antibody is an anti-CTLA-4  
25 antibody or fragment thereof.

48. The composition of claim 47, wherein said anti-CTLA-4 antibody binds  
30 an epitope on the CTLA-4 molecule comprising the B7-1 or B7-2 binding site.

49. The method of claim 43, wherein said agent is a combination of an anti-CD28 and an anti-CD3 antibody.

50. The method of claim 43, wherein said agent is a combination of an anti-  
CD28 and an anti-CD3 antibody, immobilized on a solid surface.  
35

0027205-022098

51. The method of claim 47, wherein said anti-CTLA-4 antibody is soluble.

52. The composition of claim 43, further comprising an agent that provides a primary activation signal to the T cell.

5

53. The composition of claim 52, wherein said agent that provides a primary activation signal to the T cell is an anti-CD<sub>3</sub> antibody.

54. A method for identifying an agent that modulates the expression of an HIV-1 fusion cofactor, comprising:  
10 providing a T cell expressing a cell surface receptor which binds a costimulatory molecule;

stimulating a signal transduction pathway associated with said receptor;  
contacting said T cell with said agent; and

15

determining the levels of expression of said HIV-1 fusion cofactor,  
thereby identifying an agent that modulates the expression of an HIV-1 fusion cofactor.

09027205-022093

## METHODS FOR MODULATING EXPRESSION OF AN HIV-1 FUSION COFACTOR

### Abstract of the Invention

5

Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, 10 expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.

06027205-022098




FIGURE 1




FIGURE 2






FIGURE 3

A.



B.



C.




FIGURE 4







FIGURE 5






FIGURE 7

CD3/28/CTLA-4

CD3/B7-2

CD3/28/GLY




FIGURE 8




FIGURE 9

Customer Number: 000959

Attorney's

Docket

Number GIN-005

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Methods For Modulating Expression Of An HIV-1 Fusion Cofactor  
the specification of which

(check one)

☒ X is attached hereto.

☐ was filed on \_\_\_\_\_ as

Application Serial No. \_\_\_\_\_

and was amended on \_\_\_\_\_  
(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

09027205-022093

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Carl H. June, et al.  
Serial No.: n/a  
Filed: Herewith  
For: METHODS FOR MODULATING EXPRESSION OF  
AN HIV-1 FUSION COFACTOR


BOX SEQUENCE LISTING  
Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER FOR DISKETTE OF SEQUENCE LISTING

Dear Sir:

Enclosed is a diskette which contains a computer readable form of the Sequence Listing for the patent application filed herewith. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on this diskette is identical in substance to the Sequence Listing appearing on pages 41-44 of the specification which is submitted herewith. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d).

Respectfully submitted,



Jane E. Remillard, Reg. No. 38,872  
for Amy E. Mandragouras,  
Reg. No. 36,207  
Attorney for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400

Dated: February 20, 1998  
GIN005/TRANSEQ.DOC

09027205-02209

## PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION




CLAIM FOR BENEFIT OF U.S. PROVISIONAL APPLICATION(S)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

60/037,422

(Application Serial No.)

February 21, 1997

(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

09027205.022098

# CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

(Application Serial No.)

(Filing Date)

(Status)

(patented,pending,aband.)

(Application Serial No.)

(Filing Date)

(Status)

(patented,pending,aband.)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

W. Hugo Liepmann	Reg. No. 20,407	Jean M. Silveri	Reg. No. 39,030
James E. Cockfield	Reg. No. 19,162	Jeremiah Lynch	Reg. No. 17,425
Thomas V. Smurzynski	Reg. No. 24,798	Lawrence E. Monks	Reg. No. 34,224
Ralph A. Loren	Reg. No. 29,325	David A. Lane	Reg. No. 39,261
Thomas J. Engellenner	Reg. No. 28,711	Catherine J. Kara	Reg. No. 41,106
Giulio A. DeConti, Jr.	Reg. No. 31,503	Mark D. Russett	Reg. No. 41,281
Ann Lampert Hammitte	Reg. No. 34,858	Scott D. Rothenberger	Reg. No. 41,277
Paul Louis Myers	Reg. No. 35,965	Thomas P. Grodt	Reg. No. 41,045
Elizabeth A. Hanley	Reg. No. 33,505	Linda M. Chinn	Reg. No. 31,240
Michael I. Falkoff	Reg. No. 30,833	Kevin J. Canning	Reg. No. 35,470
John V. Bianco	Reg. No. 36,748	Ivana Maravic-Magovcevic	Reg. No. P43,338
Amy E. Mandragouras	Reg. No. 36,207	Faustino A. Lichauco	Reg. No. P41,942
Anthony A. Laurentano	Reg. No. 38,220	C. Eric Schulman	Reg. No. P43,350
Jane E. Remillard	Reg. No. 38,872	Jeanne M. DiGiorgio	Reg. No. P41,710
Mark A. Kurisko	Reg. No. 38,944	Megan E. Williams	Reg. No. P43,270

Send Correspondence to Amy E. Mandragouras at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109

Direct Telephone Calls to: (name and telephone number)

Amy E. Mandragouras, (617) 227-7400

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	
Carl H. June	
Inventor's signature	Date
Residence	
Citizenship	
Post Office Address (if different)	

Full name of second inventor, if any Richard G. Carroll	
Inventor's signature	Date
Residence	
Citizenship	
Post Office Address (if different)	

Full name of third inventor, if any James L. Riley	
Inventor's signature	Date
Residence	
Citizenship	
Post Office Address (if different)	

Full name of fourth inventor, if any Daniel C. St. Louis	
Inventor's signature	Date
Residence	
Citizenship	
Post Office Address (if different)	